Di-substituted amides for enhancing glutamatergic synaptic responses

ABSTRACT

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson&#39;s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi&#39;s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

RELATED APPLICATIONS

This patent application claims the benefit of priority of provisionalapplication nos. U.S. 60/930,633, filed May 17, 2007 and U.S.60/958,069, filed Jul. 2, 2007, both of identical title to the presentapplication, each of which applications is incorporated by reference inits entirety herein.

FIELD OF THE INVENTION

This invention relates to compounds, pharmaceutical compositions andmethods for use in the prevention and treatment of cerebralinsufficiency, including enhancement of receptor functioning in synapsesin brain networks responsible for various behaviors. These brainnetworks are involved in basic functions such as breathing, to morecomplex functions such as memory and cognition. Imbalances in neuronalactivities between different brain regions may lead to a number ofdisorders, including psychiatric and neurological disorders, includingmemory impairment, Parkinson's disease, schizophrenia, attention deficitand affective or mood disorders, respiratory depression and in disorderswherein a deficiency in neurotrophic factors is implicated. In aparticular aspect, the invention relates to compounds useful fortreatment of such conditions, and methods of using these compounds forsuch treatment.

BACKGROUND OF THE INVENTION

The release of glutamate at synapses at many sites in mammalianforebrain stimulates two classes of postsynaptic ionotropic glutamatereceptors. These classes are usually referred to as AMPA andN-methyl-D-aspartic acid (NMDA) receptors. AMPA receptors mediate avoltage independent fast excitatory post-synaptic current (the fastEPSC), whereas NMDA receptors generate a voltage-dependent, slowexcitatory current. Studies carried out in slices of hippocampus orcortex, indicate that the AMPA receptor mediated fast EPSC is generallythe dominant component by far at most glutamatergic synapses, andactivation of AMPA receptors is usually a prerequisite for NMDAreceptors activation. AMPA receptors are expressed throughout thecentral nervous system. These receptors are found in high concentrationsin the superficial layers of neocortex, in each of the major synapticzones of hippocampus, and in the striatal complex, as reported byMonaghan et al., in Brain Research 324:160-164 (1984). Studies inanimals and humans indicate that these structures organize complexperceptual-motor processes and provide the substrates for higher-orderbehaviors. Thus, AMPA receptors mediate transmission in those brainnetworks responsible for a host of cognitive activities. In addition,AMPA receptors are expressed in brain regions that regulate theinspiratory drive responsible for control of breathing (Paarmann et al,Journal of Neurochemistry, 74: 1335-1345 (2000).

For the reasons set forth above, drugs that modulate and thereby enhancethe functioning of AMPA receptors could have significant benefits forintellectual performance as well as reversal of respiratory depressioninduced by pharmacological agents such as opioids and opiates, or othermeans. Such drugs should also facilitate memory encoding. Experimentalstudies, such as those reported by Arai and Lynch, Brain Research598:173-184 (1992), indicate that increasing the size of AMPAreceptor-mediated synaptic response(s) enhances the induction oflong-term potentiation (LTP). LTP is a stable increase in the strengthof synaptic contacts that follows repetitive physiological activity of atype known to occur in the brain during learning.

Compounds that enhance the functioning of the AMPA subtype of glutamatereceptors facilitate the induction of LTP and the acquisition of learnedtasks as measured by a number of paradigms. See, for example, Granger etal., Synapse 15:326-329 (1993); Staubli et al., PNAS 91:777-781 (1994);Arai et al., Brain Res. 638:343-346 (1994); Staubli et al., PNAS91:11158-11162 (1994); Shors et al., Neurosci. Let. 186:153-156 (1995);Larson et al., J. Neurosci. 15:8023-8030 (1995); Granger et al., Synapse22:332-337 (1996); Arai et al., JPET 278:627-638 (1996); Lynch et al.,Internat. Clin. Psychopharm. 11:13-19 (1996); Lynch et al., Exp.Neurology 145:89-92 (1997); Ingvar et al., Exp. Neurology 146:553-559(1997); Hampson, et al., J. Neurosci. 18:2748-2763 (1998); Porrino etal., PLoS Biol 3(9): 1-14 (2006) and Lynch and Rogers, U.S. Pat. No.5,747,492. There is a considerable body of evidence showing that LTP isthe substrate of memory. For example, compounds that block LTP interferewith memory formation in animals, and certain drugs that disruptlearning in humans antagonize the stabilization of LTP, as reported bydel Cerro and Lynch, Neuroscience 49: 1-6 (1992). Learning a simple taskinduces LTP in hippocampus that occludes LTP generated by high frequencystimulation (Whitlock et al., Science 313:1093-1097 (2006)) and amechanism that maintains LTP sustains spatial memory (Pastalkova, etal., Science 313:1141-1144 (2006)). Of significant importance to thefield of learning is the finding that in vivo treatments with a positiveAMPA-type glutamate receptor modulator restores stabilization of basaldendritic LTP in middle-aged animals (Rex, et al., J. Neurophysiol.96:677-685 (2006)).

Drugs that enhance the functioning of the AMPA receptor can effectivelyreverse opioid- and barbiturate-induced respiratory depression withoutreversing the analgesic response (Ren et al, American Journal ofRespiratory and Critical Care Medicine, 174: 1384-1391 (2006). Thereforethese drugs may be useful in preventing or reversing opioid-inducedrespiratory depression and for alleviating other forms of respiratorydepression including sedative use and sleep apnea. Excitatory synaptictransmission provides a major pathway by which neurotrophic factors areincreased within specific brain regions. As such, potentiation of AMPAreceptor function by modulators has been found to increase levels ofneurotrophins, particularly brain derived neurotrophic factor, or BDNF.See, for example, Lauterborn, et al., J. Neurosci. 20:8-21 (2000); Gall,et al., U.S. Pat. No. 6,030,968; Lauterborn, et al., JPET 307:297-305(2003); and Mackowiak, et al., Neuropharmacology 43:1-10 (2002). Otherstudies have linked BDNF levels to a number of neurological disorders,such as Parkinson's disease, Attention Deficit Hyperactivity Disorder(ADHD), autism, Fragile-X Syndrome, and Rett Syndrome (RTT). See, forexample, O′Neill, et al., Eur. J. Pharmacol. 486:163-174 (2004); Kent,et al., Mol. Psychiatry. 10:939-943 (2005); Riikonen, et al., J. ChildNeurol. 18:693-697 (2003) and Chang, et al., Neuron 49:341-348 (2006).Thus, AMPA receptor potentiators may be useful for the treatment ofthese, as well as other, neurological diseases that are the result of aglutamatergic imbalance or a deficit in neurotrophic factors.

A prototype for a compound that selectively facilitates the AMPAreceptor has been described by Ito et al., J. Physiol. 424:533-543(1990). These authors found that the nootropic drug aniracetam(N-anisoyl-2-pyrrolidinone) increases currents mediated by brain AMPAreceptors expressed in Xenopus oocytes without affecting responses byγ-aminobutyric acid (GABA), kainic acid (KA), or NMDA receptors.Infusion of aniracetam into slices of hippocampus was also shown tosubstantially increase the size of fast synaptic potentials withoutaltering resting membrane properties. It has since been confirmed thataniracetam enhances synaptic responses at several sites in hippocampus,and that it has no effect on NMDA-receptor mediated potentials (Staubliet al., Psychobiology 18:377-381 (1990) and Xiao et al., Hippocampus1:373-380 (1991)).

Aniracetam has been found to have an extremely rapid onset and washout,and can be applied repeatedly with no apparent lasting effects, whichare desirable features for behaviorally-relevant drugs. Aniracetam doespresent several disadvantages, however. The peripheral administration ofaniracetam is not likely to influence brain receptors. The drug worksonly at high concentrations (approx. 100 μM), and about 80% of the drugis converted to anisoyl-GABA following peripheral administration inhumans (Guenzi and Zanetti, J. Chromatogr. 530:397-406 (1990)). Themetabolite, anisoyl-GABA, has been found to have less activity thananiracetam. In addition to these issues, aniracetam has putative effectson a plethora of other neurotransmitter and enzymatic targets in thebrain, which makes uncertain the mechanism of any claimed therapeuticdrug effect. See, for example, Himori, et al., Pharmacology Biochemistryand Behavior 47:219-225 (1994); Pizzi et al., J. Neurochem. 61:683-689(1993); Nakamura and Shirane, Eur. J. Pharmacol. 380: 81-89 (1999);Spignoli and Pepeu, Pharmacol. Biochem. Behav. 27:491-495 (1987); Halland Von Voigtlander, Neuropharmacology 26:1573-1579 (1987); andYoshimoto et al., J. Pharmacobiodyn. 10:730-735 (1987).

A class of AMPA receptor-enhancing compounds that does not display thelow potency and inherent instability characteristic of aniracetam hasbeen described (Lynch and Rogers, U.S. Pat. No. 5,747,492). Thesecompounds, termed “Ampakines”^(R), can be substituted benzamides whichinclude, for example, 6-(piperidin-1-ylcarbonyl)quinoxaline (CX516;Ampalex^(R)). Typically, they are chemically more stable than aniracetamand show improved bio-availability. CX516 is active in animal tests usedto detect efficacious drugs for the treatment of memory disorders,schizophrenia, and depression. In three separate clinical trials, CX516showed evidence for efficacy in improving various forms of human memory(Lynch et al., Internat. Clin. Psychopharm. 11:13-19 (1996); Lynch etal., Exp. Neurology 145:89-92 (1997); Ingvar et al., Exp. Neurology146:553-559 (1997)).

Another class of Ampakines, benzoxazines, has been discovered to havevery high activity in in vitro and in vivo models for assessing theprobability of producing cognition enhancement (Rogers and Lynch; U.S.Pat. No. 5,736,543). The substituted benzoxazines are rigid benzamideanalogues with different receptor modulating properties from theflexible benzamide, CX516.

Certain substituted 2.1.3 benzoxadiazole compounds have been found to besignificantly and surprisingly more potent in animal models of attentiondeficit hyperactivity disorder (ADHD), schizophrenia and cognition thanpreviously disclosed compounds in US 2002/0055508 and US 2002/0099050.This new class of N,N-disubstituted amides (I) display significantactivity for enhancing AMPA mediated glutamateric synaptic responses.

SUMMARY OF THE INVENTION

The present invention includes, in one aspect, a compound as shown bystructure I, and described in Section II of the Detailed Description,which follows. Administration of compounds of this class has been foundto enhance AMPA mediated glutamatergic synaptic responses andsignificantly improve the behavior of rodents in the d-amphetaminestimulated locomotion assay. This behavioral assay has proven useful inassessing the efficacy of neuroleptic drugs for the treatment ofschizophrenia and ADHD. The compounds are significantly and surprisinglymore potent than previously described compounds in increasingglutamatergic synaptic responses in vivo. This activity translates intopharmaceutical compounds and corresponding methods of use, includingtreatment methods, which utilize significantly lower concentrations ofthe present compounds compared to prior art compositions. In addition,compounds within the present invention demonstrate improvedpharmacokinetic properties compared with previously described compoundsand have good oral bioavailability.

The ability of the compounds of the invention to increase AMPAreceptor-mediated responses makes the compounds useful for a variety ofpurposes. These include facilitating the learning of behaviors dependentupon glutamate receptors, treating conditions in which AMPA receptors,or synapses utilizing these receptors, are reduced in numbers orefficiency, and enhancing excitatory synaptic activity in order torestore an imbalance between brain sub-regions or increase the levels ofneurotrophic factors.

In another aspect, the invention includes a method for the treatment ofa mammalian subject suffering from a hypoglutamatergic condition, orfrom a deficiency in the number or strength of excitatory synapses, orin the number of AMPA receptors, such that memory or other cognitivefunctions are impaired. Such conditions may also cause acortical/striatal imbalance, leading to schizophrenia orschizophreniform behavior.

In another aspect, the invention includes a method for reducing orinhibiting respiratory depression in a subject having respiratorydepression, comprising administering to the subject an amount of acompound of the invention, the amount being sufficient to reduce orinhibit respiratory depression. In one embodiment of the invention, thesubject is a human. In another embodiment, the subject is a mammal. Alsoclaimed is a method for reducing or inhibiting respiratory depressioncomprising administering to the subject an amount of a compound of theinvention in combination with an opioid analgesic; examples of suchopiates include but are not limited to, alfentanil and fentanyl.

In another aspect, the invention includes a method for reducing orinhibiting breathing-related sleep disorders or sleep apnea in a subjecthaving sleep apnea, comprising administering to the subject an amount ofa compound of the invention, the amount being sufficient to reduce orinhibit the breathing related sleep disorder.

According to the methods, such a subject is treated with an effectiveamount of a compound as shown by structure I, and described in SectionII of the Detailed Description, following, in a pharmaceuticallyacceptable carrier. These and other objects and features of theinvention will become more fully apparent when the following detaileddescription of the invention is read in conjunction with theaccompanying drawings.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

The terms below have the following meanings unless indicated otherwise.Other terms not specifically defined herein which are used to describethe present invention have the same meaning given to those terms withinthe context of their use by those skilled in the art.

The term “alkyl” is used herein to refer to a fully saturated monovalentradical containing carbon and hydrogen, and which may be a straightchain, branched or cyclic. Examples of alkyl groups are methyl, ethyl,n-butyl, n-heptyl, isopropyl, 2-methylpropyl.

The symbol

is used to describe an alkylene group where the junction between the twolines represents a methylene (CH₂) group and n is an integer from 0 to7. The integer of n=0 is used to indicate that the methylene group isnon-existent.

The term “cycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 8 carbons and hydrogen in a ring.Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl and cycloheptyl. The term cycloalkyl, when used in context,may also refer to a cycloalkyl group which contains a heteroatom B group(heterocycle).

The term “bicycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 10 carbons and hydrogen in abicyclic ring. Examples of bicycloalkyl groups are bicyclo[2.2.2]octyl,bicyclo[2.2.1]heptyl, bicyclo[2.2.3]nonyl and bicylo[3.2.1]octyl.

The term “azabicycloalkyl” is used herein to refer to a fully saturatedmonovalent radical containing up to 10 carbons and hydrogen and 1nitrogen atom in a bicyclic ring. Examples of azabicycloalkyl groups ainclude 1-azabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl,1-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl and1-azabicylo[3.2.1]octyl.

The term “alkenyl” is used herein to refer to a monovalent radicalcontaining carbon and hydrogen that contains one or two sites ofun-saturation, and which may be a straight chain, branched or cyclic.Examples of alkenyl groups are ethenyl, n-butenyl, n-heptenyl,isopropenyl, cyclopentenyl, cyclopentenylethyl and cyclohexenyl.

The term “substituted” with reference to “substituted alkyl” groups(including cycloalkyl and bicycloalkyl groups), “substituted alkenyl”groups and “substituted alkynyl” groups, among other related substitutedgroups (e.g., carboxyalkyl, sulfonylalkyl), refers to one or morefunctional groups (containing from 1-8 carbon atoms, 1-7 carbon atoms,1-6 carbon atoms, 1-3 carbon atoms, 2-8 carbon atoms, 2-7 carbon atoms,2-6 carbon atoms, 3-8 carbon atoms, etc. depending upon the substituent)which are used as a substitute for H, such as alkyl containing from 1-8carbon atoms including cycloalkyl containing from 3-7 carbon atoms,aryl, substituted aryl, acyl, halogen (i.e., alkyl halos, e.g., CF₃),amido, thioamido cyano, nitro, alkynyl, azido, hydroxy, alkoxy,alkoxyalkyl, amino, alkyl and dialkyl-amino, acylamino, acyloxy,aryloxy, aryloxyalkyl, carboxyalkyl, carboxamido, thio, thioethers, bothsaturated and unsaturated cyclic hydrocarbons, heterocycles and thelike, or as otherwise described herein (see the term “substituted”hereinbelow).

The term “aryl” refers to a substituted or unsubstituted monovalentaromatic radical having a single ring (e.g., phenyl) or multiplecondensed rings (e.g., naphthyl). Other examples include heterocyclicaromatic ring groups having one or more nitrogen, oxygen, or sulfuratoms in the ring, such as oxazolyl, isoxazolyl, pyrazolyl, thiazolyl,thiadiazolyl, tetrazolyl, pyridazinyl, pyrimidyl, benzofuryl,benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolyl,isoquinolyl, imidazolyl, furyl, pyrrolyl, pyridyl, thienyl and indolyl.Thus, the term “aryl” subsumes the term “heteroaryl” as such terms areused in context.

The term “substituted” as used in the term “substituted aryl,substituted aromatic, substituted heteroaryl, or substitutedheteroaromatic”, herein signifies that one or more substituents may bepresent, said substituents being selected from atoms and groups, whichwhen present do not prevent the compound from functioning as apotentiator of AMPA receptor function. Examples of substituents that maybe present in a substituted aromatic or heteroaromatic group include,but are not limited to, groups such as (C₁-C₇) alkyl, (C₁-C₇) acyl,aryl, heteroaryl, substituted aryl and heteroaryl, halogen, cyano,nitro, amido (optionally substituted with one or two C₁-C₇ alkylgroups), thioamido (optionally substituted with one or two C₁-C₇ alkylgroups), azido, (C₂-C₇) alkynyl, (C₁-C₇) alkylhalos (e.g., CF₃),hydroxy, (C₁-C₇) alkoxy, (C₂-C₈) alkoxyalkyl, amino, (C₁-C₇) alkyl anddialkyl amino, (C₁-C₇) acylamino, (C₁-C₇) acyloxy, aryloxy, (C₁-C₇)aryloxyalkyl, (C₁-C₇) carboxyalkyl, carboxamido, thio, (C₁-C₇)thioethers, both saturated and unsaturated (C₃-C₈) cyclic hydrocarbons,(C₃-C₈) heterocycles and the like. It is noted that each of thesubstituents disclosed herein may themselves be substituted.

“Heterocycle” or “heterocyclic” refers to a carbocyclic ring wherein oneor more carbon atoms have been replaced with one or more heteroatoms (upto 6 atoms, up to 4 atoms, 1, 2 or 3 atoms) such as nitrogen, oxygen orsulfur. Examples of heterocycles include, but are not limited to,piperidine, pyrrolidine, morpholine, thiomorpholine, piperazine,tetrahydrofuran, tetrahydropyran, 2-pyrrolidinone, δ-valerolactam,δ-valerolactone and 2-ketopiperazine.

The term “substituted heterocycle” refers to a heterocycle as justdescribed that contains one or more functional groups such as loweralkyl, acyl, aryl, cyano, halogen, amido, thioamido, azido, hydroxy,alkoxy, alkoxyalkyl, amino, alkyl and dialkyl-amino, acylamino, acyloxy,aryloxy, aryloxyalkyl, carboxyalkyl, carboxamido, thio, thioethers, bothsaturated and unsaturated cyclic hydrocarbons, heterocycles and thelike, as otherwise described herein.

The term “compound” is used herein to refer to any specific chemicalcompound disclosed herein. Within its use in context, the term generallyrefers to a single compound, but in certain instances may also refer tostereoisomers and/or optical isomers (including enantiopure compounds,enantiomerically enriched compounds and racemic mixtures) of disclosedcompounds.

The term “effective amount” refers to the amount of a selected compoundof formula I that is used within the context of its intended use toeffect an intended result, for example, to enhance glutamatergicsynaptic response by increasing AMPA receptor activity. The preciseamount used will vary depending upon the particular compound selectedand its intended use, the age and weight of the subject, route ofadministration, and so forth, including the duration of its use, but maybe easily determined by routine experimentation. In the case of thetreatment of a condition or disease state, an effective amount is thatamount which is used to effectively treat the particular condition ordisease state.

The term “pharmaceutically acceptable carrier” refers to a carrier orexcipient which is not unacceptably toxic to the subject to which it isadministered. Pharmaceutically acceptable excipients are described atlength by E. W. Martin, in “Remington's Pharmaceutical Sciences.”

A “pharmaceutically acceptable salt” of an amine compound, such as thosecontemplated in the current invention, is an ammonium salt having ascounter ion an inorganic anion such as chloride, bromide, iodide,sulfate, sulfite, nitrate, nitrite, phosphate, and the like, or anorganic anion such as acetate, malonate, pyruvate, propionate, fumarate,cinnamate, tosylate, and the like.

The term “patient” or “subject” is used throughout the specification todescribe an animal, generally a mammalian animal, including a human, towhom treatment or use with the compounds or compositions according tothe present invention is provided. For treatment or use with/or of thoseconditions or disease states which are specific for a specific animal(especially, for example, a human subject or patient), the term patientor subject refers to that particular animal.

The term “sensory motor problems” is used to describe a problem whicharises in a patient or subject from the inability to integrate externalinformation derived from the five known senses in such a way as todirect appropriate physical responses involving movement and action.

The term “cognitive task” or “cognitive function” is used to describe anendeavor or process by a patient or subject that involves thought orknowing. The diverse functions of the association cortices of theparietal, temporal and frontal lobes, which account for approximately75% of all human brain tissue, are responsible for much of theinformation processing that goes on between sensory input and motoroutput. The diverse functions of the association cortices are oftenreferred to as cognition, which literally means the process by which wecome to know the world. Selectively attending to a particular stimulus,recognizing and identifying these relevant stimulus features andplanning and experiencing the response are some of the processes orabilities mediated by the human brain which are related to cognition.

The term “brain network” is used to describe different anatomicalregions of the brain that communicate with one another via the synapticactivity of neuronal cells.

The term “AMPA receptor” refers to an aggregate of proteins found insome membranes, is which allows positive ions to cross the membrane inresponse to the binding of glutamate or AMPA(DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), but not NMDA.

The term “excitatory synapse” is used to describe a cell-cell junctionat which release of a chemical messenger by one cell causesdepolarization of the external membrane of the other cell. An excitatorysynapse describes a postsynaptic neuron which has a reversal potentialthat is more positive than the threshold potential and consequently, insuch a synapse, a neurotransmitter increases the probability that anexcitatory post synaptic potential will result (a neuron will fireproducing an action potential). Reversal potentials and thresholdpotentials determine postsynaptic excitation and inhibition. If thereversal potential for a post synaptic potential (“PSP”) is morepositive than the action potential threshold, the effect of atransmitter is excitatory and produces an excitatory post synapticpotential (“EPSP”) and the firing of an action potential by the neuron.If the reversal potential for a post synaptic potential is more negativethan the action potential threshold, the transmitter is inhibitory andmay generate inhibitory post synaptic potentials (IPSP), thus reducingthe likelihood that a synapse will fire an action potential. The generalrule for postsynaptic action is: if the reversal potential is morepositive than threshold, excitation results; inhibition occurs if thereversal potential is more negative than threshold. See, for example,Chapter 7, NEUROSCIENCE, edited by Dale Purves, Sinauer Associates,Inc., Sunderland, Mass. 1997.

The term “motor task” is used to describe an endeavor taken by a patientor subject that involves movement or action.

The term “perceptual task” is used to describe an act by a patient orsubject of devoting attention to sensory inputs.

The term “synaptic response” is used to describe biophysical reactionsin one cell as a to consequence of the release of chemical messengers byanother cell with which it is in close contact.

The term “hypoglutamatergic condition” is used to describe a state orcondition in which transmission mediated by glutamate (or relatedexcitatory amino acids) is reduced to below normal levels. Transmissionconsists of the release of glutamate, binding to post synapticreceptors, and the opening of channels integral to those receptors. Theend point of the hypoglutamatergic condition is reduced excitatory postsynaptic current. It can arise from any of the three above noted phasesof transmission. Conditions or disease states which are consideredhypoglutamatergic conditions and which can be treated using thecompounds, compositions and methods according to the present inventioninclude, for example, loss of memory, dementia, depression, attentiondisorders, sexual dysfunction, movement disorders, including Parkinson'sdisease, schizophrenia or schizophreniform behavior, memory and learningdisorders, including those disorders which result from aging, trauma,stroke and neurodegenerative disorders, such as those associated withdrug-induced states, neurotoxic agents, Alzheimer's disease and aging,respiratory depression and sleep apnea. These conditions are readilyrecognized and diagnosed by those of ordinary skill in the art.

The term “cortico-striatal imbalance” is used to describe a state inwhich the balance of neuronal activities in the interconnected cortexand underlying striatal complex deviates from that normally found.‘Activity’ can be assessed by electrical recording or molecularbiological techniques. Imbalance can be established by applying thesemeasures to the two structures or by functional (behavioral orphysiological) criteria.

The term “affective disorder” or “mood disorder” describes the conditionwhen sadness or elation is overly intense and continues beyond theexpected impact of a stressful life event, or arises endogenously. Asused herein, the term “effective disorder” embraces all types of mooddisorders as described in, for example, Diagnostic and StatisticalManual of Mental Disorders, Fourth Edition (DSM IV), pages 317-391.

The term “schizophrenia” is used to describe a condition which is acommon type of psychosis, characterized by a disorder in the thinkingprocesses, such as delusions and hallucinations, and extensivewithdrawal of the individual's interest from other people and theoutside world, and the investment of it in his or her own. Schizophreniais now considered a group of mental disorders rather than a singleentity, and distinction is made between reactive and processschizophrenias. As used herein, the term schizophrenia or“schizophreniform” embraces all types of schizophrenia, includingambulatory schizophrenia, catatonic schizophrenia, hebephrenicschizophrenia, latent schizophrenia, process schizophrenia,pseudoneurotic schizophrenia, reactive schizophrenia, simpleschizophrenia, and related psychotic disorders which are similar toschizophrenia, but which are not necessarily diagnosed as schizophreniaper se. Schizophrenia and other psychotic disorders may be diagnosedusing guidelines established in, for example, Diagnostic and StatisticalManual of Mental Disorders, Fourth Edition (DSM IV) Sections 293.81,293.82, 295.10, 295.20, 295.30, 295.40, 295.60, 295.70, 295.90, 297.1,297.3, 298.8.

The term “brain function” is used to describe the combined tasks ofperceiving, integrating, filtering and responding to external stimuliand internal motivational processes.

The term “impaired” is used to describe a function working at a levelthat is less than normal. Impaired functions can be significantlyimpacted such that a function is barely being carried out, is virtuallynon-existent or is working in a fashion that is significantly less thannormal. Impaired functions may also be sub-optimal. The impairment offunction will vary in severity from patient to patient and the conditionto be treated.

The term “respiratory depression” as used herein refers to a variety ofconditions characterized by reduced respiratory frequency andinspiratory drive to cranial and spinal motor neurons. Specifically,respiratory depression refers to conditions where the medullary neuralnetwork associated with respiratory rhythm generating activity does notrespond to accumulating levels of PCO₂ (or decreasing levels of PO₂) inthe blood and subsequently under stimulates motorneurons controllinglung musculature.

The term “sleep apnea” as used herein refers to breathing-related sleepdisorders of which there are two types: central and obstructive. CentralSleep Apnea is defined as a neurological condition causing cessation ofall respiratory effort during sleep, usually with decreases in bloodoxygen saturation, if the brainstem center controlling breathing shutsdown there's no respiratory effort and no breathing. The person isaroused from sleep by an automatic breathing reflex, so may end upgetting very little sleep at all. Obstructive sleep apnea ischaracterized by repetitive pauses in breathing during sleep due to theobstruction and/or collapse of the upper airway and followed by anawakening to breathe. Respiratory effort continues during the episodesof apnea.

The term “pro-drug” as used herein refers to a metabolically labilederivative that is pharmacologically inactive in the parent form butthat is rapidly metabolized in human or animal plasma to apharmacologically active form. Examples of pro-drugs as used hereininclude but in no way are limited to, where applicable, esterderivatives of hydroxyl containing moieties or amide derivatives ofamine containing moieties, such esters or amides include, but are notlimited to those formed from substituted or un-substituted natural orun-natural amino acids.

The term “co-administration” or “combination therapy” is used todescribe a therapy in which at least two active compounds in effectiveamounts are used to treat a disease state or condition as otherwisedescribed herein at the same time. Although the term co-administrationpreferably includes the administration of two active compounds to thepatient at the same time, it is not necessary that the compounds beadministered to the patient at the same time, although effective amountsof the individual compounds will be present in the patient at the sametime.

II. Compounds of the Present Invention

The present invention is directed, in one aspect, to compounds havingthe property of enhancing AMPA receptor function. These are compoundshaving the structure I, below:

wherein:W is oxygen, sulfur or CH═CH;X, Y and Z are independently selected from the group consisting of —N,or —CR, wherein:R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched orun-branched alkyl, which may be un-substituted or substituted,wherein:R¹ is H, —C₁-C₆ branched or un-branched alkyl which, may beun-substituted or substituted, F═O or S,A is H, or —C₁-C₆ branched or un-branched alkyl, which may beun-substituted or substituted, —C₂-C₆ branched or un-branched alkenyl,which may be un-substituted or substituted, —C₂-C₆ branched orun-branched alkynyl, which may be un-substituted or substituted, —C₃-C₇cycloalkyl which may be un-substituted or substituted, —C₃-C₇alkylcycloalkyl which may be un-substituted or substituted, aryl orheterocycle which may be un-substituted or substituted, alkylaryl whichmay be un-substituted or substituted, alkylheterocycle which may beun-substituted or substituted n=0, 1, 2, 3, 4, 5, or 6;

is a —C₃-C₇ cycloalkyl, which may be un-substituted or substituted, a—C₄-C₇ azacycloalkyl, which may be un-substituted or substituted, aC₇-C₁₀ bicycloalkyl which may be un-substituted or substituted, a—C₇-C₁₀ azabicycloalkyl which may be un-substituted or substituted, arylwhich may be un-substituted or substituted or a heterocycle which may beun-substituted or substituted;

B is C═, C—R^(a), O, N, S, C═O, S═O or SO₂;

R^(a) is H, a halogen (preferably F), OH, O-alkyl, cyano, or a —C₁-C₆alkyl group which is un-substituted or substituted and which optionally,forms a C₃-C₇ cycloalkyl group with D; and D is absent when B is O, S,S═O, C═O or SO₂, or if present, is bonded to B when B is C═, —C—R^(a) orN, and is H, a halogen (preferably F), OR^(b), a —C₁-C₆ branched orun-branched alkyl, which may be un-substituted or substituted and whichoptionally, forms a C₃-C₇ cycloalkyl group with R^(a), a —C₂-C₆ branchedor un-branched alkenyl, which may be un-substituted or substituted, a—C₂-C₆ branched or un-branched alkynyl, which may be un-substituted orsubstituted, a —C₃-C₇ cycloalkyl which may be un-substituted orsubstituted, an aryl which may be un-substituted or substituted, aheterocycle which may be un-substituted or substituted, a —C₂-C₇carboxyalkyl which may be un-substituted or substituted, a carboxyarylwhich may be un-substituted or substituted, a carboxyheteroaryl whichmay be un-substituted or substituted, a —C₁-C 7 sulfonylalkyl which maybe un-substituted or substituted, a sulfonylaryl which may beun-substituted or substituted or a sulfonylheteroaryl which may beun-substituted or substituted, or when B is —C—R^(a), R^(a) and Doptionally form a ═N—R^(c) or a ═N—OR^(c) group with B, wherein R^(c) isH or an unsubstituted or substituted C₁-C₇ alkyl group, or when B is—C—R^(a), R^(a) and D optionally form a ═N—R^(c) or a ═N—OR^(c) groupwith B, wherein R^(c) is H or an unsubstituted or substituted C₁-C₇alkyl group; and R^(b) is H, a —C₁-C₇ alkyl group which may be branchedor un-branched, un-substituted or substituted or a —C₂-C₇ acyl groupwhich may be un-substituted or substituted;or a pharmaceutically acceptable salt, solvate, pro-drug or polymorphthereof.

Preferred embodiments include compounds according to formula II below:

wherein:A is —C₁-C₆ branched or un-branched alkyl, which may be un-substitutedor substituted, a C₃-C₇ cycloalkyl which may be un-substituted orsubstituted;n is 0, 1, 2, or 3;

B is C—R^(a), O or C═O;

R^(a) is H, F, —OH or alkyl andD is absent (when B is O), is H or OH when R^(a) is H or alkyl, or is Fwhen R^(a) is F, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.

A preferred embodiment includes compounds according to formula IIIbelow:

wherein:A is a C₁-C₆ alkyl which may be substituted or un-substituted;

B is C—R^(a), O or C═O;

R^(a) is H, F, —OH or alkyl andD is absent (when B is O), is H or OH when R^(a) is H or alkyl, or is Fwhen R^(a) is F, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.

A further preferred embodiment includes compounds according to formulaIV below:

wherein:A is a C₁-C₆ alkyl which may be substituted or un-substituted,n is 0, 1 or 2, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.

A further preferred embodiment includes compounds according to formula Vbelow:

wherein:A is a C₁-C₆ alkyl which may be substituted or un-substituted,R¹ is H, F, or C₁-C₄ alkyl,R² is H, F, CN, a heterocycle which may be substituted or un-substitutedor OR³,R³ is H, C₁-C₆ alkyl which may be substituted or un-substituted, or apharmaceutically acceptable salt, solvate, or polymorph thereof.

A further preferred embodiment includes compounds according to formulaVI below:

wherein:A is a C₁-C₆ alkyl which may be substituted or un-substituted,R is H, or C₁-C₄ alkyl, or a pharmaceutically acceptable salt, solvate,or polymorph thereof.

A yet further preferred embodiment includes compounds according toformula VII below:

wherein:

B is C—R^(a), O or C═O;

R^(a) is H, F, —OH or alkyl andD is absent (when B is O), is H or OH when R^(a) is H or alkyl, or is Fwhen R^(a) is F, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.

In a yet further preferred embodiment compounds are included accordingto formula VIII below:

wherein:

Bis C—R^(a), O or C═O;

R^(a) is H, F, —OH or alkyl andD is absent (when B is O), is H or OH when R^(a) is H or alkyl, or is Fwhen R^(a) is F, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.

A yet further preferred embodiment includes compounds according toformula IX below:

wherein:A is a C₁-C₆ alkyl which may be substituted or un-substituted,R¹ is H, or C₁-C₄ alkyl,R² is H, or a C₁-C₆ alkyl which may be substituted or un-substituted,R³ is H, or a C₁-C₆ alkyl which may be substituted or un-substituted,R⁴ is H, or a C₁-C₆ alkyl which may be substituted or un-substituted, ora pharmaceutically acceptable salt, solvate, or polymorph thereof.

In a further aspect, the present invention provides compounds ofFormulas I-IX selected from:

-   N-Cycloheptyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4,4-Dimethylcyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-spiro[2.5]oct-6-yl[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclopentyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclobutyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclohexyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclopentyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclobutyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-tetrahydro-2H-pyran-4-yl[2,1,3]-benzoxadiazole-5-carboxamide-   N-D₃-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(Tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Ethyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclohexyl-N-ethyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(Cyclohexylmethyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Benzyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(tetrahydrofuran-2-ylmethyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-pyridin-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-phenyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Cyclopropyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Tetrahydro-2H-pyran-4-yl-N-(2,2,2-trifluoroethyl)-[2,1,3]-benzoxadiazole-5-carboxamide    tert-Butyl-4-[([2,1,3]-benzoxadiazol-5-ylcarbonyl)(methyl)amino]piperidine-1-carboxylate-   N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide    hydrochloride-   N-Methyl-N-(1-methylpiperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(1-Acetylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(1-Formylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-[1-(methylsulfonyl]piperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzothiadiazole-5-carboxamide-   N-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(1-oxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-tetrahydro-2H-pyran-4-ylquinoxaline-6-carboxamide-   N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-[4-(Hydroxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-[4-(Methoxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4,4-Difluorocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4-fluorocyclohex-3-en-1-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4-trans-Hydroxycyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Hydroxy-4-methylcyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-4-Ethynyl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(4-trans-Hydroxycyclohexyl)-N-D₃-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carbothioamide-   N-(4-cis-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-[trans-4-(2H-tetrazol-2-yl)cyclohexyl]-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Azidocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-4-Aminocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(cis-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(trans-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(3-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(3,3-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(2-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(2-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(2,2-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(2-Hydroxytetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide-   N-(2-Hydroxytetrahydro-2H-pyran-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl    N,N-dimethyl glycinate hydrochloride-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl    L-alaninate hydrochloride-   N—(R)-Tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N—(R)-tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl    glycinate hydrochloride-   N-2-(4-Morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide-   N-Methyl-N-2-(4-morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide    hydrochloride-   N-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carbothioamide-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl    L-valinate hydrochloride-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexyl    N,N-dimethyl glycinate hydrochloride-   N-Methyl-N-tetrahydro-2H-pyran-4-ylmethyl-[2,1,3]-benzoxadiazole-5-carboxamide-   trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexyl    glycinate hydrochloride

III. Synthesis

The synthesis of the compounds of the invention is preferably carriedout by the following Scheme. Alternative syntheses by analogy relying onmethodology that exists in the art also may be used.

In the Scheme, Steps A and B, used to produce the N-methylamines 4(A=Me) are carried out using standard conditions, for example, amines 1are dissolved in a suitable organic solvent, for exampledichloromethane, a base (e.g. NEt₃ or NaHCO₃ in water) is added and thena solution of benzyloxycarbonyl chloride (Cbz-Cl) in an organic solvente.g. dichloromethane is added, which results in the formation of thebenzyl carbamates 2 (step A). The carbamates 2 are then reduced with forexample lithium aluminium hydride (LiAlH₄) in a suitable organic solventfor example tetrahydrofuran (THF) to give amines 4 (A=Me, Step B).Amines 4, may be alternatively prepared by reductive amination ofketones 3 in the presence of an amine (ANH₂), using standard conditions,for example Pd/C in an appropriate solvent for example ethanol, as shownin Step C. Acid chloride 8a is synthesized starting with4-amino-3-nitrobenzoic acid 5, by firstly oxidizing using sodiumhypochlorite in ethanol in the presence of potassium hydroxide to giveintermediate 6 (Step D) and then reducing 6 with triethyl phosphite(P(OEt)₃) in a suitable solvent, for example ethanol, to givebenzofurazan carboxylic acid 7 as shown in Step E. The carboxylic acid 7was transformed to the acid chloride 8a in Step F by refluxing withthionyl chloride in toluene. The benzofurazan carboxylic acid 7 can betransformed into amides 9a and 10a using amines 1 and 4, respectively,using standard amide coupling conditions for example1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI),O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate(HBTU), N-hydroxybenzotriazole (HOBT), dimethylaminopyridine (DMAP) andtriethyalamine in a suitable solvent e.g. dichloromethane (Step G).Alternatively, acid chloride 8a can be transformed into amides 9a and10a using standard coupling conditions with amines 1 and 4,respectively, in the presence of a base for example triethylamine indichloromethane as solvent or aqueous sodium hydrogen carbonate in waterand dichloromethane (Step H). The benzothiadiazole amides 9b and 10b areprepared from the commercially available benzothiadiazole acid chloride8b using standard coupling conditions with amines 1 and 4, respectively,in the presence of a base for example triethylamine in dicholoromethaneas solvent, or aqueous sodium hydrogen carbonate in water anddichloromethane (Step H). The quinoxaline-6-carboxylic acid chloride 8cis prepared by condensation of commercially available 3,4-diaminobenzoicacid with glyoxal followed by refluxing with thionyl chloride and acatalytic amount of DMF in toluene using standard procedures. 8c wasconverted to the amides 9c and 10c by coupling reaction with amines land4 using the standard procedures described previously (Step H).Alternatively, amides 10a-c can be prepared from amides 9a-c bydeprotonation with a suitable base for example sodium hydride in asolvent e.g. N,N-dimethylformamide (DMF) followed by treatment with analkylating agent (RX) to yield 10a-c (Step I). The thioamides 11 can beprepared from amides 10 using standard procedures, for example, byreacting 10 with phosphorous pentoxide in a suitable solvent e.g.toluene (Step J).

IV. Method of Treatment

According to one aspect of the invention, a method is provided fortreating a mammalian subject suffering from a hypoglutamatergiccondition, or from deficiencies in the number or strength of excitatorysynapses or in the number of AMPA receptors. In such a subject, memoryor other cognitive functions may be impaired, or cortical/striatalimbalance may occur, leading to loss of memory, dementia, depression,attention disorders, sexual dysfunction, movement disorders,schizophrenia or schizophreniform behavior. Memory disorders andlearning disorders, which are treatable according to the presentinvention include those disorders that result from, for example, aging,trauma, stroke and neurodegenerative disorders. Examples ofneurodegenerative disorders include, but are not limited to, thoseassociated with drug-induced states, neurotoxic agents, Alzheimer'sdisease, and aging. These conditions are readily recognized anddiagnosed by those of ordinary skill in the art and treated byadministering to the patient an effective amount of one or morecompounds according to the present invention.

In another aspect, the invention provides a method for reducing orinhibiting respiratory depression in a subject having such a condition,comprising administering to the subject an amount of a compound of theinvention, the amount being sufficient to reduce or inhibit respiratorydepression. In a further aspect of the invention, a method is providedfor reducing or inhibiting respiratory depression comprisingadministering to the subject an amount of a compound of the invention incombination with an opiate; examples of such opiates include but are notlimited to, alfentanil and fentanyl.

In a further aspect, the invention provides a method for reducing orinhibiting breathing-related sleep disorders or sleep apnea in a subjecthaving sleep apnea, comprising administering to the subject an amount ofa compound of the invention, the amount being sufficient to reduce orinhibit the breathing related sleep disorder.

In the present invention, the method of treatment comprisesadministering to the subject in need of treatment, in a pharmaceuticallyacceptable carrier, an effective amount of a compound having the FormulaI below:

wherein:W is oxygen, sulfur or CH═CH;X, Y and Z are independently selected from the group consisting of —N,or —CR, wherein:R is H, —Br, —Cl, —F, —CN, —NO₂, —OR¹, —NR¹ ₂, —C₁-C₆ branched orun-branched alkyl, which may be un-substituted or substituted,wherein:R¹ is H, —C₁-C₆ branched or un-branched alkyl which, may beun-substituted or substituted, F O or SA is H, or —C₁-C₆ branched or un-branched alkyl, which may beun-substituted or substituted, —C₂-C₆ branched or un-branched alkenyl,which may be un-substituted or substituted, —C₂-C₆ branched orun-branched alkynyl, which may be un-substituted or substituted, —C₃-C₇cycloalkyl which may be un-substituted or substituted, —C₃-C₇alkylcycloalkyl which may be un-substituted or substituted, aryl orheterocycle which may be un-substituted or substituted, alkylaryl whichmay be un-substituted or substituted, alkylheterocycle which may beun-substituted or substitutedn=0, 1, 2, 3, 4, 5, or 6;

is a —C₃-C₇ cycloalkyl, which may be un-substituted or substituted, a—C₄-C₇ azacycloalkyl, which may be un-substituted or substituted, aC₇-C₁₀ bicycloalkyl which may be un-substituted or substituted, a—C₇-C₁₀ azabicycloalkyl, which may be un-substituted or substituted,aryl which may be un-substituted or substituted or a heterocycle whichmay be un-substituted or substituted;

B is C—R^(a), O, N, S, C═O, S═O or SO₂,

R^(a) is H, a halogen (preferably F), OH, O-alkyl, cyano, or a —C₁-C₆alkyl group which is un-substituted or substituted and which optionally,forms a C₃-C₇ cycloalkyl group with D; and D is absent when B is O, S,C═O, S═O or SO₂, or if present, is bonded to B when B is C═, C—R^(a) orN, and is H, a halogen (preferably F), OR^(b), a —C₁-C₆ branched orun-branched alkyl, which may be un-substituted or substituted, and whichoptionally, forms a C₃-C₇ cycloalkyl group with R^(a), a —C₂-C₆ branchedor un-branched alkenyl, which may be un-substituted or substituted, a—C₂-C₆ branched or un-branched alkynyl, which may be un-substituted orsubstituted, a —C₃-C₇ cycloalkyl which may be un-substituted orsubstituted, an aryl which may be un-substituted or substituted, aheterocycle which may be un-substituted or substituted, a —C₂-C₇carboxyalkyl which may be un-substituted or substituted, a carboxyarylwhich may be un-substituted or substituted, a carboxyheteroaryl whichmay be un-substituted or substituted, a —C₁-C₇ sulfonylalkyl which maybe un-substituted or substituted, a sulfonylaryl which may beun-substituted or substituted or a sulfonylheteroaryl which may beun-substituted or substituted, or when B is —C—R^(a), R^(a) and Doptionally form a ═N—R^(c) or a ═N—OR^(c) group with B, wherein R^(c) isH or an unsubstituted or substituted C₁-C₇ alkyl group; andR^(b) is H, a —C₁-C₇ alkyl group which may be branched or un-branched,un-substituted or substituted or a —C₂-C₇ acyl group which may beun-substituted or substituted;or a pharmaceutically acceptable salt, solvate, pro-drug or polymorphthereof, optionally in combination with a pharmaceutically acceptablecarrier, additive or excipient.

In the present invention, the method of treatment comprisesadministering to the subject in need of treatment, in a pharmaceuticallyacceptable carrier, an effective amount of a compound having theFormulas II-IX as previously defined.

Compounds according to the present invention exhibit enhancedbioavailability in most instances due, at least in part, to enhancedpharmacokinetics exhibited by the present compounds. Accordingly, thepresent compounds may be favorably formulated into pharmaceuticalcompositions in a variety of dosage forms, and in particular, oraldosage forms.

As noted above, treatment of a subject according to the method of theinvention is useful for enhancing AMPA receptor activity, and thus maybe used to facilitate the learning of behaviors dependent upon AMPAreceptors, and to treat conditions, such as memory impairment, in whichAMPA receptors, or synapses utilizing these receptors, are reduced innumbers or efficiency. The method is also useful for enhancingexcitatory synaptic activity in order to restore an imbalance betweenbrain sub-regions, which may manifest itself in schizophrenia orschizophreniform behavior, or other behavior as described above. Thecompounds administered in accordance with the method have been found tobe more effective than previously described compounds in enhancing AMPAreceptor activity, as shown in the in vivo tests described below.

V. Biological Activity A. Enhancement of AMPA Receptor Function In Vivo

Synaptic responses mediated by AMPA receptors are increased according tothe method of the invention, using the compounds described herein.

The electrophysiological effects of the invention compounds were testedin vivo in anesthetized animals according to the following procedures.Animals are maintained under anesthesia by phenobarbital administeredusing a Hamilton syringe pump. Stimulating and recording electrodes areinserted into the perforant path and dentate gyrus of the hippocampus,respectively. Once electrodes are implanted, a stable baseline of evokedresponses are elicited using single monophasic pulses (100 μs pulseduration) delivered at 3/min to the stimulating electrode. Field EPSPsare monitored until a stable baseline is achieved (about 20-30 min),after which a solution of test compound is injected intraperitoneallyand evoked field potentials are recorded. Evoked potentials wererecorded for approximately 2 h following drug administration or untilthe amplitude of the field EPSP returns to baseline. In the latterinstance, it is common that an iv administration is also carried outwith an appropriate dose of the same test compound. Invention compoundswere assayed in the in vivo electrophysiology assay described above anddata for representative test compounds is shown in column 1 in Table 1.Compounds of the invention are significantly more active in increasingthe amplitude of the field EPSP in the rat dentate gyrus following i.p.dosing than CX516 (1-(quinoxalin-6-ylcarbonyl)piperidine; U.S. Pat. No.5,773,434, US2002/0055508) which gave a 9% increase in amplitude of thefield EPSP at 50 mg/kg i.p.

TABLE 1 ²Inhibition of d- Compound Example ¹In vivo AmphetamineStimulated Number Electrophysiology Locomotion 4 17% 80% 5 15% NT 6 10%37% 11 12% NT 12 20% 66% 17 12% 23% 25  10%³ NT 33  16%³ NT 36   5%³ NT37 18% 100%  40 18% 84% 41 18% 67% 45 19% 122%  51 21% 100%  53 17% 94%54  18%³ NT 56 19% NT 73 13% NT ¹% increase in the amplitude of thefield EPSP in the dentate gyrus of rat @ 10 mpk i.p. ²% Inhibition ofd-amphetamine stimulated locomotion in mice @ 18 mpk i.p. ³Dosedintravenously. NT = Not testedB. Behavioral Testing: Inhibition of d-Amphetamine Stimulated Locomotion

The ability of the invention compounds to inhibit d-Amphetaminestimulated locomotor activity was assayed according to the followingprocedure. Male CD1 mice, 25-30 gm body weight, were brought into theexperimental room and allowed at least 30 min of acclimation. Each mousewas placed into the testing enclosure with an infrared beam array thatautomatically monitors the animal's activity. Mice were habituated inthe testing enclosure for to 20 min, and then returned to their homecage. Mice were dosed intraperitoneally with test compound inappropriate vehicle 5 minutes before d-Amphetamine injection (2 mpk).Ten minutes after d-Amphetamine injection, mice were tested forlocomotor activity for a total of 15 minutes. The data was computercollected and expressed as “arbitrary movement units.” All data wereanalyzed by comparing the groups treated with the test compound to thevehicle control group. The data for test compounds is shown in Table 1,column 2. The data shown is the % inhibition of hyperactivity induced byacute administration of 2 mg/kg d-amphetamine in mice. The compoundstested produced a statistically significant inhibition of d-amphetaminestimulated locomotion.

VI. Administration, Dosages, and Formulation

As noted above, the compounds and method of the invention increaseglutamatergic synaptic responses mediated by AMPA receptors, and areuseful for the treatment of hypoglutamatergic conditions. They are alsouseful for treatment of conditions such as impairment of memory or othercognitive functions, brought on by a deficiency in the number orstrength of excitatory synapses, or in the number of AMPA receptors.They may also be used in the treatment of schizophrenia orschizophreniform behavior resulting from a cortical/striatal imbalance,and in facilitation of learning of behaviors dependent upon AMPAreceptors.

In subjects treated with the present compounds, pharmaceuticalcompositions and methods memory or other cognitive functions may beimpaired or cortical/striatal imbalance may occur, leading to loss ofmemory, dementia, depression, attention disorders, sexual dysfunction,movement disorders, schizophrenia or schizophreniform behavior. Memorydisorders and learning disorders, which are treatable according to thepresent invention, include those disorders that result from aging,trauma, stroke and neurodegenerative disorders. Examples ofneurodegenerative disorders include, but are not limited to, thoseassociated with drug-induced states, neurotoxic agents, Alzheimer'sdisease, and aging. These conditions are readily recognized anddiagnosed by those of ordinary skill in the art and treated byadministering to the patient an effective amount of one or morecompounds according to the present invention.

Generally, dosages and routes of administration of the compound will bedetermined according to the size and condition of the subject, accordingto standard pharmaceutical practices. Dose levels employed can varywidely, and can readily be determined by those of skill in the art.Typically, amounts in the milligram up to gram quantities are employed.The composition may be administered to a subject by various routes, e.g.orally, transdermally, perineurally or parenterally, that is, byintravenous, subcutaneous, intraperitoneal, or intramuscular injection,among others, including buccal, rectal and transdermal administration.Subjects contemplated for treatment according to the method of theinvention are animals, especially mammals, including humans, companionanimals, domesticated animals, laboratory animals, and the like.

Formulations containing the compounds according to the present inventionmay take the form of solid, semi-solid, lyophilized powder, or liquiddosage forms, such as, for example, tablets, capsules, powders,sustained-release formulations, solutions, suspensions, emulsions,suppositories, creams, ointments, lotions, aerosols, patches or thelike, preferably in unit dosage forms suitable for simple administrationof precise dosages.

Pharmaceutical compositions according to the present invention comprisean effective amount of one or more compounds according to the presentinvention and typically include a conventional pharmaceutical carrier orexcipient and may additionally include other medicinal agents, carriers,adjuvants, additives and the like. Preferably, the composition will beabout 0.5 to 75% by weight or more of a compound or compounds of theinvention, with the remainder consisting essentially of suitablepharmaceutical excipients. For oral administration, such excipientsinclude pharmaceutical grades of mannitol, lactose, starch, magnesiumstearate, sodium saccharine, talcum, cellulose, glucose, gelatin,sucrose, magnesium carbonate, and the like. If desired, the compositionmay also contain minor amounts of non-toxic auxiliary substances such aswetting agents, emulsifying agents, or buffers.

Liquid compositions can be prepared by dissolving or dispersing thecompounds (about 0.5% to about 20% by weight or more), and optionalpharmaceutical adjuvants, in a carrier, such as, for example, aqueoussaline, aqueous dextrose, glycerol, or ethanol, to form a solution orsuspension. For use in oral liquid preparation, the composition may beprepared as a solution, suspension, emulsion, or syrup, being suppliedeither in liquid form or a dried form suitable for hydration in water ornormal saline.

When the composition is employed in the form of solid preparations fororal administration, the preparations may be tablets, granules, powders,capsules or the like. In a tablet formulation, the composition istypically formulated with additives, e.g. an excipient such as asaccharide or cellulose preparation, a binder such as starch paste ormethyl cellulose, a filler, a disintegrator, and other additivestypically used in the manufacture of medical preparations.

An injectable composition for parenteral administration will typicallycontain the compound in a suitable i.v. solution, such as sterilephysiological salt solution. The composition may also be formulated as asuspension in a lipid or phospholipid, in a liposomal suspension, or inan aqueous emulsion.

Methods for preparing such dosage forms are known or will be apparent tothose skilled in the art; for example, see Remington's PharmaceuticalSciences (17th Ed., Mack Pub. Co., 1985). The composition to beadministered will contain a quantity of the selected compound in apharmaceutically effective amount for effecting increased AMPA receptorcurrents in a subject.

The following examples illustrate but are not intended in any way tolimit the invention.

Unless otherwise stated, all temperatures are given in degrees Celsius.Unless otherwise stated, all NMR spectra are ¹H NMR spectra and wereobtained in deuterochloroform or deuterated DMSO as solvent usingtetramethylsilane as an internal standard. All names of Examplecompounds conform to IUPAC nomenclature as provided by the computersoftware ChemSketch by ACD Labs.

I. Chemical Methods Intermediate 1 [2,1,3]-Benzoxadiazole-5-carboxylicacid

In a 3 L reactor fitted with mechanical stirring, reflux condenser,thermometer and nitrogen inlet, KOH (72.46 g) was dissolved in ethanol(250 ml) and water (250 ml). 4-Amino-3-nitrobenzoic acid (100 g) wasadded and the orange suspension was heated to 65-70° C. within 30minutes. The resulting suspension was stirred at the same temperaturefor 45 minutes and cooled to 0° C. ±5° C. within 30 minutes. Acommercially available (13% w/w) solution of sodium hypochlorite (448.93g) was added drop wise within 1.5 hours at 0° C. ±5° C. The reactionmixture was stirred at the same temperature for 2 hours and controlledby TLC (CHCl₃ 100/acetone 2/acetic acid 1). Water (350 ml) was addedwithin 15 minutes at 0° C. ±5° C. to give a fine yellow suspension. Thereaction mixture was then acidified with a 6N HCl solution (239 ml)until 0.5<pH<1 was reached. Sodium chloride (58.44 g) was added and theresulting suspension was stirred at 0° C. ±5° C. for 1.5 hours undernitrogen. The solid was collected by filtration, washed with 3×400 mlwater and dried (40° C., 30 mbars, 12 hours) to yield 83.6 g (88.8%yield) of [2,1,3]-benzoxadiazole-5-carboxylic acid N-oxide.

In a 2 L reactor fitted with mechanical stirring, thermometer, additionfunnel, reflux condenser and nitrogen inlet,[2,1,3]-benzoxadiazole-5-carboxylic acid N-oxide (80 g) was dissolved inabsolute ethanol (800 ml). To this solution triethyl phosphite (114.05g) was added within 10 minutes at 70° C. ±2° C. The resulting mixturewas heated to reflux (76-78° C.) and maintained for 2 hours. Monitoringthe reaction by TLC(CHCl₃ 100/acetone 2/acetic acid 1) showed completereaction. The solvent was removed under vacuum (30 mbars, 40° C.) whichyielded a black oil (180 g). Water (400 ml) was added and the mixturewas extracted with ethyl acetate (400 and 160 ml). The organic phase wasextracted with 850 ml water containing NaOH (9.5<pH<10). The aqueousphase was separated and extracted with ethyl acetate (3×240 ml). Theaqueous phase was acidified (78 ml 6 N HCl) to 1<pH<2 at 5° C. ±2° C.which resulted in the crystallization of the yellow product, which wasfiltered off and dried (40° C., 30 mbars, 12 hours) to yield 65.56 g(90% yield) [2,1,3]-benzoxadiazole-5-carboxylic acid: mp=160-161° C., ¹HNMR (300 MHz, DMSO) δ 13.8 (s, 1H); 8.57 (s, 1H); 8.56 (d, 1H, J=0.6Hz); 7.87 ppm (d, 1H, J=0.6 Hz).

Intermediate 2 [2,1,3]-Benzoxadiazole-5-carbonylchloride

In a 500 ml reactor fitted with mechanical stirring, thermometer,addition funnel, reflux is condenser and nitrogen inlet,[2,1,3]-benzoxadiazole-5-carboxylic acid (28 g) was suspended in toluene(245 ml). To this suspension was added thionyl chloride (39.4 g) and DMF(0.35 ml). The resulting mixture was heated to reflux and maintained for3 hours. A short pass column was installed and toluene was distilled(atmospheric pressure, 124 ml) off to remove excess reagent. Aftercooling the remaining toluene was distilled off, which resulted in athick oil. This oil was distilled (90° C., 2 mm Hg) to remove impuritiesand the product crystallized on standing (79.8% yield), mp: 55-58° C.

Example 1 N-Cycloheptyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a solution of cycloheptanone (1.12 g, 10 mmol) in 40 ml of ethanolwas added a methylamine (2.5 ml of a 33% solution in ethanol) and 220 mgof Pd on C (10%) were added, and the mixture hydrogenated at 50 psi overnight. The solids were filtered off and the mixture concentrated undervacuum to give a pale yellow oil. This material and 1.2 ml oftriethylamine were dissolved in 10 ml of dichloromethane and a solutionof [2,1,3]-benzoxadiazole-5-carbonylchloride (730 mg, 4 mmol) was addedslowly. After stirring the mixture for 2 hours, the organic phase waswashed with 1N HCl and conc. NaHCO₃ solution, dried over magnesiumsulfate, and then concentrated under vacuum to give a white solid, aftertrituration with ether (405 mg, 37%). Mp: 80-81° C., ¹H NMR (300 MHz,CDCl₃, rotamers) δ 7.93 (m, 1H); 7.80 (s, 1H); 7.43-7.37 (m, 1H);4.75-4.60 and 3.70-3.55 (m+m, 1H); 3.01 and 2.87 (s+s, 3H); 2.00-1.20ppm (m, 12H).

Example 2N-(4,4-Dimethylcyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Methylamine, generated by heating a mixture of methylamine hydrochloride(10 g) and is sodium hydroxide pellets (18 g), was condensed (dry icetrap) into a solution of 4,4-dimethylcyclohexanone (1.0 g, 7.9 mmol) in40 ml of methanol and 20 ml of THF. 10% Pd on C (400 mg) was added andthe mix was hydrogenated at room temperature over night. The solids werefiltered off, and the mixture concentrated under vacuum. This materialand triethylamine (2 ml) were dissolved in chloroform (50 ml) and asolution of [2,1,3]-benzoxadiazole-5-carbonylchloride (900 mg, 4.9mmol), in chloroform (40 ml), was added slowly at room temperature.After stirring the mixture for 1 hour, the organic phase was washed with1N HCl and conc. NaHCO₃ solution, dried over sodium sulfate, andconcentrated under vacuum to yield an oil, which was purified usingsilica gel chromatography eluting with chloroform/ethyl acetate/hexane(10:20:70), to give a white solid, after crystallization frommethyl-t-butyl ether (MTBE)/hexane (38 mg). Mp=143-5° C., ¹H NMR (300MHz, CDCl₃, rotamers) δ 7.91 (d, 1H, J=8.7 Hz); 7.81 (sb, 1H); 7.45-7.36(m, 1H); 4.52-4.35 and 3.45-3.30 (m+m, 1H); 3.04 and 2.89 (s+s, 3H) and1.95-0.80 ppm (m, 14H).

Example 3N-Methyl-N-spiro[2.5]oct-6-yl-[2,1,3]-benzoxadiazole-5-carboxamide

A solution of benzyl spiro[2.5]oct-6-yl carbamate (1.1 g, 3.85 mmol) inTHF (40 ml) was slowly added to LiAlH₄ (1.0 g) in THF (40 ml), at roomtemperature, and the mixture stirred for 2 hours. The mixture was thencooled with ice/water and hexane (35 ml) was added, followed by carefuladdition of a solution of sodium hydroxide (1 g) in water (4 ml). Celitewas added, the mixture was filtered and the filtrate concentrated undervacuum. A solution of triethylamine (2 ml) in chloroform (60 ml) wasadded to the residue followed by a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (704 mg, 6 mmol), inchloroform (10 ml). After stirring the mixture for 1 hour, the organicphase was washed with 1N sulfuric acid and conc. NaHCO₃ solution, theaqueous phases were re-extracted with chloroform (100 ml), and thecombined organic phases were dried over magnesium sulfate, concentratedunder vacuum and chromatographed on silica gel eluting with ethylacetate/hexane (30:70) to give a white solid (410 mg, 37% yield), aftercrystallization from dichloromethane/MTBE: Mp=107-109° C., ¹H NMR (300MHz, CDCl₃, rotamers) δ 7.91 (d, 1H, J=9.3 Hz); 7.82 (s, 1H); 7.47-7.35(m, 1H); 4.66-4.50 and 3.55-3.40 (m+m, 1H); 3.05 and 2.91 (s+s, 3H);2.10-1.55 and 0.99-0.86 (m, 8H) and 0.40-0.20 ppm (m, 4H).

Example 4 N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a solution of cyclohexylamine (4 ml, 17.4 mmol) and triethylamine (3ml) in 50 ml of dichloromethane was slowly added benzylchloroformate(2.4 ml, 17.4 mmol) and the mixture stirred at room temperatureovernight. The solution was extracted with 1N HCl and conc. NaHCO₃solution, the organic phase dried over magnesium sulfate, andconcentrated under vacuum to yield 2.85 g of white solid. The solid wasdissolved in THF (50 ml), slowly added to LiAlH₄ (1.09 g) in diethylether (50 ml) and the mixture heated to 70° C. for 1 hour. The mixturewas then cooled with an ice/water bath, hexane (40 ml) was added,followed by careful addition of a solution of sodium hydroxide (5 g) in10 ml of water. Celite was added and the mixture was filtered, followedby concentration under vacuum. To a solution of the resulting residue intriethylamine (3 ml) and dichloromethane (50 ml) was slowly added[2,1,3]-benzoxadiazole-5-carbonylchloride (1.095 g, 6 mmol). Afterstirring the mixture for 1 hour, the organic phase was washed with 1NHCl and conc. NaHCO₃ solution, dried over magnesium sulfate, andconcentrated under vacuum to give a white solid (1.45 g). The materialwas chromatographed on a silica gel eluting with chloroform/ethylacetate (4:1) to to give a white solid (406 mg, 26% yield). Mp=134-5°C., LC-MS, MH⁺=260; ¹H NMR (300 MHz, CDCl₃, 2 rotamers) δ 7.91 (d, 1H,J=9.3 Hz); 7.81 (s, 1H); 7.45-7.36 (m, 1H); 4.6-4.45 and 3.5-3.3 (m+m,3H); 3.01 and 2.87 (s+s, 1H); 1.95-1.00 ppm (m, 10H).

Example 5 N-Cyclopentyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from cyclopentanone and[2,1,3]-benzoxadiazole-5-carbonylchloride using the procedures describedfor Example 2. Mp=110-111° C., LC-MS, MH⁺=246; ¹H NMR (300 MHz, CDCl₃, 2rotamers) δ 7.91 (d, 1H, J=9.3 Hz); 7.83 (s, 1H); 7.42 (d, 1H, J=9.3Hz); 5.1-4.9 and 4.15-3.95 (m+m, 1H); 2.995 (s, 3H); 2.1-1.40 ppm (m,8H).

Example 6 N-Cyclobutyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from cyclobutylamine hydrochloride and[2,1,3]-benzoxadiazole-5-carbonylchloride according to the proceduresdescribed for Example 4. Mp=51-2° C., LC-MS, MH⁺=232; ¹H NMR (300 MHz,CDCl₃, 2 rotamers) δ 7.91 (d, 1H, J=9.0 Hz); 7.81 (s, 1H); 7.42 (d, 1H,J=9.0 Hz); 5.1-4.9 and 4.35-4.15 (m+m, 1H); 3.110 (s, 3H); 2.40-1.40 ppm(m, 6H).

Example 7 N-Cyclohexyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a solution of cyclohexylamine (1 ml) and triethylamine (1.7 ml) indichloromethane (20 ml) was added a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (730 mg, 4 mmol) indichloromethane (10 ml). After stirring the mixture for 1 hour, theorganic phase was washed with 1N HCl and conc. NaHCO₃ solution, driedover magnesium sulfate, and concentrated under vacuum. The residue wastriturated with ether to give a white solid (265 mg, yield=27%).Mp=172-173° C., ¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 7.90 (d, 1H,J=9.0 Hz); 7.82 (d, J=9.0 Hz, 1H); 6.09 (“s”, NH, 1H), 4.05-3.97 (m, 1H)and 2.09-1.18 ppm (m, 10H).

Example 8 N-Cyclopentyl-[2,1,3]-benzoxadiazole-5-carboxamide

This compound was prepared from cyclopentylamine using the proceduredescribed for Example 7. Mp: 169-170° C., ¹H NMR (300 MHz, CDCl₃) δ8.17-8.14 (m, 1H), 7.90 (dd, 1H, J=9.0 and 0.6 Hz); 7.81 (dd, J=9.0 and0.9 Hz, 1H); 6.25 (“s”, NH, 1H), 4.50-4.35 (m, 1H) and 2.16-1.45 ppm (m,8H).

Example 9 N-Cyclobutyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from cyclobutylamine using the proceduredescribed for Example 7. Mp: 175-176° C., ¹H NMR (300 MHz, CDCl₃) δ8.20-8.17 (m, 1H), 7.90 (dd, J=9.0 and 0.9 Hz, 1H); 7.82 (dd, J=9.0 and0.9 Hz, 1H); 6.46 (“s”, NH, 1H), 4.70-4.50 (m, 1H) and 2.50-1.60 ppm (m,6H).

Example 10 and Example 11N-(cis-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(trans-4-cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

t-Butyl methyl-(4-oxocyclohexyl)carbamate (4.54 g, 20 mmol) andtoluenesulphonylmethyl isocyanide (5.07 g, 26 mmol) were dissolved indry tetrahydrofuran (100 ml) and cooled to 0° C. Potassium tert-butoxide(5.16 g, 46 mmol) was added slowly and the mixture was allowed to warmto 20° C. and stir for 3 hours. The reaction mixture was evaporated todryness and partitioned between ethyl acetate (150 ml) and water (50ml). The organic layer was separated, dried over magnesium sulfate andevaporated. The crude product was chromatographed on a silica geleluting with ethyl acetate/hexane (66:34) to give 1.43 g of tert-butylmethyl-(4-cyanocyclohexyl)carbamate.

t-Butyl methyl-(4-cyanocyclohexyl)carbamate (710 mg, 3 mmol) wasdissolved in dichloromethane (20 ml) and trifluoroacetic acid (3 ml) wasadded. The solvent was evaporated after 2 hours, the residue wasre-dissolved in a 4N HCl (3 ml) solution in dioxane and the solventevaporated. Dichloromethane (30 ml) and NEt₃ (2 ml) were added to theresidue followed by a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (548 mg, 3 mmol) indichloromethane (10 ml). After stirring the mixture for 1 hour at roomtemperature, the organic phase was washed with 1N HCl and conc. NaHCO₃solution, dried over magnesium sulfate, and concentrated under vacuum.The material was purified on a silica gel column eluting with ethylacetate/chloroform (1:1) to give 170 mg ofN-(cis-4-cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideas a white solid and as the less polar isomer. Mp=222-223° C., ¹H NMR(300 MHz, CDCl₃, rotamers) δ 7.93 (d, 1H, J=9.0 Hz); 7.85 (s, 1H), 7.42(d, J=9.0 Hz, 1H); 4.65-4.50 and 3.55-3.40 and 3.15-2.80 (m, 5H) and2.20-1.30 ppm (m, 8H).

The more polarN-(trans-4-cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas obtained as a white solid after crystallization from diethyl ether(180 mg). Mp=180-181° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93 (d,1H, J=8.7 Hz); 7.83 (s, 1H), 7.42 (d, J=8.7 Hz, 1H); 4.60-4.45 and3.60-3.40 and 3.05-2.80 (m, 5H) and 2.50-1.40 ppm (m, 8H).

Example 12N-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide

Methylamine, generated by heating a mixture of methylamine hydrochloride(10 g) and sodium hydroxide pellets (18 g), was condensed (dry ice trap)into a solution of tetrahydro-4H-pyran-4-one (1.0 g, 10 mmol) inmethanol (50 ml). 10% Pd on C (350 mg) was added and the mixture washydrogenated at room temperature for 7 hours. The solids were filteredoff and the filtrate concentrated under vacuum. The residue wasdissolved in chloroform (70 ml) and triethylamine (2 ml) and a solutionof [2,1,3]-benzoxadiazole-5-carbonylchloride (500 mg, 2.73 mmol) inchloroform (10 ml) was added slowly. After stirring the reaction mixturefor 30 minutes, the organic phase was extracted with 100 ml of water andsulfuric acid (→pH 2) and the aqueous phase re-extracted with chloroform(100 ml), dried over magnesium sulfate, and concentrated under vacuum togive an oil. The crude product was purified by silica gel chromatographyeluting ethyl acetate/hexane (75:25) and chloroform/acetone (85:15) togive the title product as a white solid after crystallization from ethylacetate. Mp=160-2° C., LC-MS, MH⁺=262; ¹H NMR (300 MHz, CDCl₃, 2rotamers) δ 7.93 (d, 1H, J=9.0 Hz); 7.84 (s, 1H); 7.42 (d, 1H, J=9.0Hz); 4.90-4.70 and 4.20-3.10 (m+m, 5H); 2.927 (s, 3H); 2.1-1.5 ppm (m,4H).

Example 13N-D₃-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide

The compound was prepared according to the procedure for Example 12 fromD₃-methylamine and tetrahydro-4H-pyran-4-one. Mp=165-166° C., ¹H NMR(300 MHz, CDCl₃, 2 rotamers) δ 7.93 (d, 1H, J=9.0 Hz); 7.84 (s, 1H);7.42 (d, 1H, J=9.0 Hz); 4.90-4.70 and 4.20-3.10 (m+m, 5H) and 2.1-1.5ppm (m, 4H).

Example 14N-(Tetrahydro-2H-pyran-4-0)-[2,1,3]-benzoxadiazole-5-carboxamide

A mixture of hydroxylamine hydrochloride (5.56 g), sodium acetate (6.56g) and tetrahydro-4H-pyran-4-one (4 g, 40 mmol) in ethanol (100 ml) wasrefluxed over night. The solids were filtered off and the solventevaporated. The remaining material was suspended in 100 ml of dry THFand decanted. LiAlH₄ (6.07 g) was slowly added and the mixture wasrefluxed for 1 hour. The cooled mixture was quenched with 10% sodiumhydroxide solution, celite was added, and the solids were filtered off.The solvent was evaporated and the residue re-dissolved indichloromethane (10 ml) and triethylamine (1 ml). This mixture wasslowly added to a solution of [2,1,3]-benzoxadiazole-5-carbonylchloride(365 mg, 2.0 mmol) in dichloromethane (10 ml) and stirred at roomtemperature for 0.5 h. The mixture was washed with 1N HCl (100 ml) andNaHCO₃ (100 ml) solution and the aqueous re-extracted withdichloromethane (100 ml). The combined organics were dried overmagnesium sulfate, and concentrated under vacuum to give a white solid(410 mg). Mp=204-205° C., ¹H NMR (300 MHz, CDCl₃) δ 8.20-8.18 (m, 1H),7.92 (dd, 1H, J=9.3 and 1.2 Hz); 7.82 (dd, 1H, J=9.3 and 1.2 Hz);6.25-6.10 (m, NH, 1H); 4.33-4.17 (m, 1H), 4.07-4.00 (m, 2H), 3.59-3.51(m, 2H), 2.07-2.03 (m, 2H) and 1.69-1.58 ppm (m, 2H).

Example 15N-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide wasprepared from 3-aminotetrahydropyran hydrochloride and[2,1,3]-benzoxadiazole-5-carbonylchloride using the procedure describedfor Example 7. Mp=204-205° C., ¹H NMR (300 MHz, CDCl₃) δ 8.24-8.10 (m,1H), 7.93 (dd, 1H, J=9.0 and 0.9 Hz); 7.84 (dd, 1H, J=9.0 and 1.2 Hz);6.70-6.60 (m, NH, 1H); 4.24-4.22 (m, 1H), 3.86-3.60 (m, 4H) and1.97-1.61 ppm (m, 4H).

Example 16N-Methyl-N-(tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide (371mg, 1.5 mmol) was added to a suspension of sodium hydride (216 mg, 9mmol) in dry DMF (5 ml), followed by methyl iodide (1.0 ml) and themixture was stirred at 20° C. for 1 hour. The solvent was evaporatedunder vacuum, dichloromethane (30 ml) was added and the organic phasewas is washed with 1N HCl (100 ml) and NaHCO₃ solution (100 ml). Theaqueous was re-extracted with dichloromethane (100 ml), the organicsdried over magnesium sulfate and concentrated under vacuum to give thetitle compound as a white solid after trituration with diethyl ether(186 mg). Mp: 134-135° C., ¹H NMR (300 MHz, CDCl₃) δ 7.93 (d, 1H, J=9.0Hz); 7.83 (s, 1H); 7.40 (d, 1H, J=9.0 Hz); 4.70-3.20 (m, 4H), 3.01 (sb,3H) and 2.10-1.50 ppm (m, 4H).

Example 17N-Ethyl-N-tetrahydro-2H-pyran-4-[2,1,3]-benzoxadiazole-5-carboxamide

To a solution of tetrahydro-4H-pyran-4-one (1.0 g, 10 mmol) in methanol(60 ml) was added ethylamine hydrochloride (815 mg, 10 mmol), 1 ml ofNEt₃, and 10% Pd on C (350 mg). The mixture was hydrogenated at roomtemperature over night (18 hours). The solids were filtered, washed withmethanol (20 ml) and concentrated under vacuum. The residue wasdissolved in chloroform (70 ml) and NEt₃ (2 ml) and a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (600 mg, 3.28 mmol) inchloroform (10 ml) was added slowly. After stirring for 0.5 h, themixture was washed with water (100 ml) and H₂SO₄ (→pH 2) and NaHCO₃solution (100 ml). The aqueous was extracted with chloroform (100 ml)and the combined organics were dried over MgSO₄ and concentrated undervacuum to give an oil.

Chromatography on silica gel eluting with ethyl acetate/hexane (75:25)and chloroform/acetone (85:15), gave white solid after crystallizationfrom diethyl ether (470 mg). Mp=102-4° C., LC-MS, MH⁺=276; ¹H NMR (300MHz, CDCl₃, 2 rotamers) δ 7.93 (d, 1H, J=9.0 Hz); 7.80 (s, 1H); 7.38 (d,1H, J=9.0 Hz); 4.75-4.45 and 4.15-3.90 and 3.75-3.05 (m+m+m, 7H);2.04-1.05 ppm (m, 7H).

Example 18 N-Cyclohexyl-N-ethyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from ethylamine hydrochloride andcyclohexanone using the procedures described for Example 17. Aftersilica gel chromatography the product was isolated as a white solid.Mp=51-2° C., LC-MS, MH⁺=274; ¹H NMR (300 MHz, CDCl₃, 2 rotamers) δ 7.91(d, 1H, J=9.0 Hz); 7.78 (s, 1H); 7.76 (d, 1H, J=9.0 Hz); 4.4-4.3 and3.55-3.2 (m+m, 3H); 1.95-0.95 ppm (m, 13H).

Example 19N-(Cyclohexylmethyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from cyclohexyl-4-methylamine using themethods described for Example 4 and was isolated as a white solid.Mp=71-2° C., LC-MS, MH⁺=274; ¹H NMR (300 MHz, CDCl₃, 2 rotamers) δ7.94-7.78 (m, 2H); 7.48-7.38 (m, 1H); 3.43+3.16 (d+d, 2H); 3.10 and 3.01(s+s, 3H); 1.90-1.55 and 1.47-0.95 and 0.73-0.57 ppm (m+m+m, 11H).

Example 20 N-Benzyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from N-benzyl-N-methylamine and[2,1,3]-benzoxadiazole-5-carbonylchloride according to the procedurepreviously described.N-Benzyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide was isolated as awhite solid. Mp=105-106° C., LC-MS, MH⁺=268; ¹H NMR (300 MHz, CDCl₃, 2rotamers) δ 7.96-7.86 (m, 1H); 7.90 (d, 1H, J=9.6 Hz); 7.43-7.30 (m,5H); 7.19-7.13 (m, 1H); 4.78+4.56 (s+s, 2H); 3.11 and 2.94 ppm (s+s,3H).

Example 21N-Methyl-N-(tetrahydrofuran-2-ylmethyl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared by N-methylation of the product of the reaction oftetrahydrofuran-2-methylamine and[2,1,3]-benzoxadiazole-5-carbonylchloride as described for thepreparation of Examples 7 and 16.N-Methyl-N-(tetrahydrofuran-2-ylmethyl)-[2,1,3]-benzoxadiazole-5-carboxamideWas isolated as a pale yellow oil. LC-MS, MH⁺=262; ¹H NMR (300 MHz,CDCl₃, 2 rotamers) δ 7.94-7.85 (m, 2H); 7.51-7.44 (m, 1H); 4.31-3.22 (m,5H); 3.18 and 3.14 (s+s, 3H); 2.18-1.25 ppm (m, 4H).

Example 22 N-Methyl-N-pyridin-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from 3-aminopyridine using the experimental proceduresdescribed for Example 4.N-Methyl-N-pyridin-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide wasisolated as a yellow oil. LC-MS, MH⁺=255; ¹H NMR (300 MHz, CDCl₃) δ 8.44(d, 1H, J=4.8 Hz); 8.39 (d, 1H, J=2.1 Hz); 7.74 (s, 1H); 7.72 (d, 1H,J=9 Hz); 7.51 (dd, 1H, J=8.4 and 2.1 Hz); 7.35 (d, 1H, J=9 Hz); 7.27(dd, 1H, J=8.4 and 4.8 Hz); 3.56 ppm (s, 3H).

Example 23 N-Methyl-N-phenyl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from N-methylaniline and[2,1,3]-benzoxadiazole-5-carbonylchloride using the procedure describedfor Example 7. N-Methyl-N-phenyl-[2,1,3]-benzoxadiazole-5-carboxamidewas isolated as a yellow oil. LC-MS, MH⁺=254; ¹H NMR (300 MHz, CDCl₃) δ7.74 (s, 1H); 7.64 (d, 1H, J=9.6 Hz); 7.34 (d, 1H, J=9.6 Hz); 7.29-7.09(m, 5H); 3.54 ppm (s, 3H).

Example 24N-Cyclopropyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Cyclopropyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamidewas prepared from tetrahydro-4H-pyran-4-one and cyclopropylamine usingthe procedures described for Example 17 and was isolated as a whitesolid. Mp=108-109° C., LC-MS, MH⁺=288; ¹H NMR (300 MHz, CDCl₃) δ 7.91(t, 1H, J=1.0 and 1.0 Hz, 1H); 7.76 (dd, J=9.2 and 1.0 Hz, 1H); 7.51(dd, J=9.2 and 1.0 Hz, 1H); 4.50-4.39 (m, 1H); 4.11-4.06 (m, 2H);3.58-3.49 (m, 2H); 2.70-2.60 (m, 1H); 2.28-2.12 (m, 2H); 1.90-1.85 (m,2H); 0.75-0.53 ppm (m, 41-1).

Example 25N-Tetrahydro-2H-pyran-4-yl-N-(2,2,2-trifluoroethyl)-[2,1,3]-benzoxadiazole-5-carboxamide

The title compound was prepared from tetrahydro-4H-pyran-4-one and2,2,2-trifluoroethylamine using the procedures described for Example 17and was isolated as a white solid. Mp=134-135° C., LC-MS, MH⁺=330; ¹HNMR (300 MHz, CDCl₃) δ 7.79 (dd, J=9.2 and 1.0 Hz, 1H); 7.91-7.85 (m,1H); 7.40 (dd, J=9.2 and 1.0 Hz, 1H); 4.20-3.85 (m, 5H); 3.35-3.15 (m,2H); 2.02-1.65 ppm (m, 4H).

Example 26tert-Butyl-4-[([2,1,3]-benzoxadiazol-5-ylcarbonyl)(methyl)amino]piperidine-1-carboxylate

Methylamine (generated by heating a mixture of 10 g of methylaminehydrochloride and 18 g of sodium hydroxide) was condensed into asolution of Boc-4-piperidone (3.5 g, 17.6 mmol) in methanol (30 ml) andTHF (30 ml). 10% Pd on C (600 mg) was added and the mixture washydrogenated at room temperature for 18 hours. The solids were filteredoff, washed with methanol (20 ml) and concentrated under vacuum. Theresidue was dissolved in chloroform (50 ml) and NEt₃ (4 ml), and asolution of [2,1,3]-benzoxadiazole-5-carbonylchloride (2.1 g, 11.5 mmol)in dichloromethane (20 ml) was added slowly. After stirring the mixturefor 1 h, the organic phase was washed with water (100 ml) and H₂SO₄ (→pH2) and NaHCO₃ solution (100 ml). The aqueous was extracted withchloroform (100 ml), the organics combined, dried (MgSO₄) andconcentrated under vacuum to give an oil. The crude product was purifiedby silica gel chromatography eluting with ethyl acetate/hexane (40:60)→(60:40) to give a white solid after crystallization from MTBE/hexane(3.14 g). Mp=98-100° C., LC-MS, MH⁺=361; ¹H NMR (300 MHz, CDCl₃) δ 7.93(d, J=9.0 Hz, 1H); 7.84 (s, 1H); 7.42 (d, J=9.0 Hz, 1H); 4.80-3.40 (m,5H); 3.10-2.85 (m, 3H); 1.90-1.60 (m, 4H); 1.47 ppm (s, 9H).

Example 27N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide.Hydrochloride

tert-Butyl-4-[([2,1,3]-benzoxadiazol-5-ylcarbonyl)(methyl)amino)]piperidine-1-carboxylate(1.2 g, 3.33 mmol) was dissolved in chloroform (30 ml) and TFA (3 ml)was added and the mixture was stirred at room temperature for 2 hours.The mixture was concentrated under vacuum and the residue was dissolvedin chloroform (30 ml) ethanol (30 ml) and conc. HCl (1 ml). The mixturewas concentrated under vacuum to give a solid that was washed with amixture of chloroform, ethanol and THF to yield an off white solid (920mg). Mp>260° C., ¹H NMR (300 MHz, DMSO) δ 9.04-8.78 (m, 2H); 8.20-8.05(m, 2H); 7.62-7.52 (m, 1H); 4.70-4.50 and 3.88-3.72 (m, 1H); 3.30-2.70(m, 7H) and 2.20-1.80 ppm (m, 4H).

Example 28N-Methyl-N-(1-methylpiperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared by N-methylation ofN-methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide asdescribed for Example 16 and isolated as a beige solid aftercrystallization from ethyl acetate/dichloromethane. Mp>260° C., LC-MS,MH⁺=275.2; ¹H NMR (300 MHz, CDCl₃) δ 7.28-7.20 (m, 2H); 6.67 (d, J=9.6Hz, 1H); 3.70-6.57 and 2.90-2.70 (m, 1H); 3.70-1.95 ppm (m, 14H).

Example 29N-(1-Acetylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochloride (0.58 g, 1.9 mmol) was suspended in chloroform (50 ml),and acetic anhydride (2 ml) and triethylamine (4 ml), were added. Afterstirring for 1 h, the mixture was washed with water (100 ml) and H₂SO₄(→pH 2) and NaHCO₃ solution (100 ml). The aqueous was extracted withchloroform (2×100 ml) and the combined organics dried (MgSO₄) andconcentrated under vacuum. The residue was purified by silica gelchromatography eluting with ethyl acetate/chloroform/methanol (50:45:5)to give a white solid after crystallization from ethylacetate/MTBE/hexane (470 mg). Mp=173-175° C., ¹H NMR (300 MHz, CDCl₃) δ7.93 (d, J=9.0 Hz, 1H); 7.85 (s, 1H); 7.42 (d, J=9.0 Hz, 1H); 4.90-4.70and 4.05-3.80 (m, 5H); 2.89 (sb, 3H); 2.13 (sb, 3H), 1.95-1.60 ppm (m,4H).

Example 30N-(1-Formylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochloride (0.5 g, 1.7 mmol) was suspended in chloroform (20 ml) andTHF (20 ml) and triethylamine (6 ml), was added. A mixture of formicacid (1 ml) and acetic anhydride (1 ml) was stirred for 1.5 h at roomtemperature and then slowly added to the suspension. After stirring themixture for 1 h, it was washed with water (100 ml) and H₂SO₄ (→pH 2) andNaHCO₃ solution (100 ml). The aqueous was extracted with chloroform(2×100 ml) and the combined organics were dried (MgSO₄), concentratedunder vacuum, and purified by silica gel chromatography, eluting withethyl acetate/chloroform/methanol (50:45:5) to give a white solid (341mg). Mp=163-165° C., ¹H NMR (300 MHz, CDCl₃) δ 8.05 (s, 1H), 7.93 (d,J=9.3 Hz, 1H); 7.86 (s, 1H); 7.42 (d, J=9.3 Hz, 1H); 4.90-4.45 and3.85-2.60 (m, 5H); 2.88 (sb, 3H); and 1.95-1.60 ppm (m, 4H).

Example 31N-Methyl-N-[1-(methylsulfonyl]piperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochloride (0.38 g, 1.3 mmol) was suspended in chloroform (70 ml) andtriethylamine (2 ml) was added. A solution of methane sulfonyl chloride(0.14 g, 1.26 mmol) in chloroform (10 ml) was added and the mixture wasstirred at 20° C. for 2 h. The mixture was washed with water (50 ml) andH₂SO₄ (→pH 2) and NaHCO₃ solution (50 ml) and the aqueous re-extractedwith dichloromethane (2×50 ml). The combined organics were dried(MgSO₄), concentrated under vacuum, and the crude product was purifiedon a silica gel column eluting with dichloromethane/THF (85:15) to givea white crystalline product, after crystallization from MTBE/hexane (204mg). Mp=177-179° C., ¹H NMR (300 MHz, CDCl₃) δ 7.93 (d, J=9.3 Hz, 1H);7.85 (s, 1H); 7.42 (d, J=9.3 Hz, 1H); 4.75-4.46 and 4.10-3.90 and3.10-2.40 (m, 5H); 2.92 (s, 3H), 2.83 (s, 3H) and 2.10-1.70 ppm (m, 4H).

Example 32N-Methyl-N-(tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzothiadiazole-5-carboxamide

N-Methyltetrahydro-2H-pyran-4-amine (0.4 g, 3.4 mmol),[2,1,3]-benzothiadiazole-5-carboxylic acid (0.23 g, 1.4 mmol), DMAP (0.2g: 1.6 mmol), HOBT (0.2 g, 1.5 mmol), triethylamine (1.0 ml) and EDCI (1g, 6.4 mmol) were dissolved in DMF (30 ml). The mixture was stirred atroom temperature for 18 h and then concentrated under vacuum. Chloroform(100 ml) was added and the mixture washed with water (100 ml) and H₂SO₄(→pH 2) and NaHCO₃ solution (100 ml). The aqueous was extracted withchloroform (100 ml) and the combined organics were dried (MgSO₄),concentrated under vacuum, and the crude product was purified on asilica gel column eluting with chloroform/THF (90:10), to give theproduct as an oil which crystallized on standing. Mp=106-108° C., ¹H NMR(300 MHz, CDCl₃, rotamers) δ 8.06 (d, J=9.0 Hz, 1H); 8.01 (s, 1H); 7.60(d, J=9.0 Hz, 1H); 4.92-4.75 and 4.15-3.10 (m, 5H); 3.10-2.80 (m, 3H)and 2.05-1.50 ppm (s, 4H).

Example 33N-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

Tetrahydro-2H-thiopyran-4-one (1.0 g, 8.6 mmol) was dissolved inmethanol (40 ml), and methylamine in ethanol (3.3 ml of a 33% solution)was added and the mixture stirred at room to temperature for 1 h. Themixture was cooled to −78° C. and a suspension of LiBH₄ (0.34 g) in THF(10 ml) was added and stirred for 18 h whilst warming up to roomtemperature. Water (1 ml) was added and then evaporated and the residuedissolved in chloroform (20 ml). Triethylamine (2 ml) was added and themixture cooled to 0° C. before adding slowly a solution of[2,1,3]-benzoxadiazole-5-carbonylchloride (1.28 g, 7 mmol) in chloroform(15 is ml). The mixture was stirred for 0.5 h and then washed with water(100 ml) and HCl (→pH 2) and NaHCO₃ solution (100 ml). The aqueous wasextracted with chloroform (100 ml) and the combined organics were dried(MgSO₄) and concentrated under vacuum to give a white solid aftertrituration with diethyl ether (1.6 g). Mp=155-156° C., ¹H NMR (300 MHz,CDCl₃, rotamers) δ 7.92 (d, J=9.3 Hz, 1H); 7.83 (sb, 1H); 7.40 (d, J=9.3Hz, 1H); 4.60-4.45 and 3.50-3.30 (m, 1H); 3.10-2.40 (m, 7H) and2.20-1.85 ppm (s, 4H).

Example 34N-Methyl-N-(1-oxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-S-carboxamide(0.83 mg, 3 mmol) was dissolved in THF (30 ml) and methanol (20 ml). Asolution of sodium periodate (0.71 g) in water (30 ml) was added and themixture stirred over night. The solvents were evaporated and the productwas purified by silica gel chromatography eluting withchloroform/THF/methanol (60:20:20), to give two sulfone isomers. Theless polar isomer was isolated as a white solid (0.35 g). Mp=172-173°C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.94 (d, J=9.3 Hz, 1H); 7.87(sb, 1H); 7.43 (d, J=9.3 Hz, 1H); 4.80-4.65 and 3.70-3.50 (m, 1H); 3.0(s, 3H), 3.30-1.60 ppm (m, 8H). The more polar isomer was isolated as a2:1 mixture with the less polar isomer (0.45 g). Mp=145-146° C., ¹H NMR(300 MHz, CDCl₃, rotamers) δ 7.96-7.85 (m, 2H); 7.45-7.39 (m, 1H);4.80-4.65 and 3.70-3.40 (m, 1H); 3.0 (s, 3H), 3.30-1.70 ppm (m, 8H).

Example 35N-Methyl-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide(0.5 g, 1.8 mmol) was dissolved in chloroform (40 ml) andm-chloroperbenzoic acid (0.93 g) was added and stirred for 1 h. Themixture was washed with Na₂CO₃ solution (100 ml), dried over MgSO₄ andevaporated and the residue crystallized from dichloromethane/diethylether to give a white solid (44 mg). Mp=238-239° C., ¹H NMR (300 MHz,CDCl₃) δ 7.95 (d, J=9.0 Hz, 1H); 7.87 (sb, 1H); 7.41 (d, J=9.0 Hz, 1H);4.90-4.70 (m, 1H); 3.35-3.10 (m, 4H); 2.97 (s, 3H); 2.60-2.10 ppm (m,4H).

Example 36 N-Methyl-N-tetrahydro-2H-pyran-4-ylquinoxaline-6-carboxamide

To a suspension of quinoxaline-6-carboxylic acid (0.7 g, 4 mmol) andN-methyltetrahydro-2H-pyran-4-amine (0.7 g, 6 mmol), in DMF (6 ml) anddichloromethane (6 ml), were added DMAP (0.49 g, 4 mmol), HOBT (0.54 g,4 mmol), NEt₃ (1.6 ml) and EDCI (1.26 g). The reaction mixture wasstirred at room temperature for 4 h and then concentrated under vacuum.The crude product was purified on a silica gel column eluting withchloroform/methanol/triethylamine (95:5:0.5) to give an oil (1.5 g)which formed a beige solid upon trituration with dichloromethane/diethylether. Mp=130-131° C., LC-MS, MH⁺=272; ¹H NMR (300 MHz, CDCl₃) δ 8.91(s, 2H); 8.18 (d, J=8.4 Hz, 1H); 8.11 (s, 1H); 7.79 (d, J=8.4 Hz, 1H);4.95-3.50 (m, 5H); 3.07 and 2.91 (s+s, 3H); 2.02-1.65 ppm (m, 4H).

Example 37N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

1,4-Cyclohexanedione mono-ethylene ketal (3.12 g, 20 mmol), methylaminehydrochloride (1.35 g, 20 mmol) and triethylamine (2.42 g) weredissolved in methanol (80 ml) and 10% Pd on C (1 g) was added and themix hydrogenated at room temperature at 50 PSI for 2 h. The solids werefiltered off, washed with methanol (40 ml) and the mixture concentratedunder vacuum. The product was dissolved in chloroform (75 ml) andtriethylamine (4 ml) was added followed by slow addition of a solutionof [2,1,3]-benzoxadiazole-5-carbonylchloride (2.74 g, 15 mmol) inchloroform (15 ml). After stirring the mixture for 1 h it was washedwith water (100 ml) and HCl (→pH 2) and NaHCO₃ solution (100 ml). Theaqueous was extracted with chloroform (100 ml) and the combined organicswere dried (MgSO₄) and concentrated under vacuum to give the product asa yellow solid (4.2 g). This material was dissolved in THF (30 ml), and2N HCl (40 ml) was added and the mixture stirred overnight. The THF wasevaporated and the remaining aqueous was extracted with dichloromethane(100 ml), washed with water (100 ml) and sat. NaHCO₃ solution (100 ml),and dried over MgSO₄. The solvent was evaporated under vacuum to give abeige solid (3.5 g) which was crystallized from dichloromethane/diethylether to give a white solid. Mp=183-184° C., LC-MS, MH⁺=274; ¹H NMR (300MHz, CDCl₃, rotamers) δ 7.95 (d, J=9.0 Hz, 1H); 7.87 (m, 1H); 7.40 (“d”,J=9.0 Hz, 1H); 5.10-4.95 and 4.10-3.90 (m, 1H); 2.93 (“s”, 3H);2.70-1.95 ppm (s, 8H).

Example 38N-[4-(Hydroxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide (0.41g, 1.5 mmol) was dissolved in chloroform (10 ml), hydroxylaminehydrochloride (0.63 g) and triethylamine (1.6 ml) were added, and themixture stirred overnight. Evaporation of the solvent and tochromatography of the residue on silica gel, eluting withchloroform/ethyl acetate (3:2), gave a white solid (0.37 g). Mp=197-198°C., NMR (300 MHz, CDCl₃) δ 8.49 (s, 1H); 7.93 (d, J=9.0 Hz, 1H); 7.86(m, 1H); 7.43 (d, J=9.0 Hz, 1H); 4.90-4.70 and 3.80-3.35 (m, 1H); 2.99and 2.88 (s+s, 3H); 2.80-1.50 ppm (s, 8H).

Example 39N-[4-(Methoxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide (0.41g, 1.5 mmol) was dissolved in chloroform (10 ml), methoxylaminehydrochloride (0.75 g) and triethylamine (1.6 ml) were added, and themixture stirred overnight. Evaporation of the solvent and chromatographyof the residue on silica gel, eluting with chloroform/ethyl acetate(3:2), gave a white solid (0.32 g). Mp=167-168° C., NMR (300 MHz, CDCl₃)δ 7.93 (d, J=9.3 Hz, 1H); 7.84 (m, 1H); 7.42 (d, J=9.3 Hz, 1H);4.85-4.70 and 3.80-3.30 (m, 1H); 3.83 (s, 3H); 2.99 and 2.88 (s+s, 3H);2.60-1.60 ppm (s, 8H).

Example 40 and Example 41N-(4,4-Difluorocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(4-fluorocyclohex-3-en-1-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide (1.5g, 5.5 mmol) was dissolved in dichloromethane (50 ml) and cooled to 0°C. Diethylaminosulfur trifluoride, “DAST” (1.8 ml, 2.4 equivalents) wasadded slowly and the mixture stirred at room temperature for 3 h. Thesolution was diluted with dichloromethane (100 ml) and NaHCO₃ solutionwas added slowly until pH 9 was reached. The organic phase was washedwith brine, dried over MgSO₄ and evaporated. The crude product waschromatographed on a silica gel eluting with hexane/ethyl acetate(65:35) to giveN-(4,4-difluorocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.32 g) as a white solid after trituration with ether. Mp=137-138° C.,LC-MS, MH⁺=296; ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93 (d, J=9.0 Hz,1H); 7.84 (s, 1H); 7.41 (d, J=9.0 Hz, 1H); 4.75-4.60 and 3.65-3.55 (m,1H); 3.01 and 2.91 (s+s, 3H); 2.30-1.60 ppm (s, 8H).

A second product was isolated asN-(4-fluorocyclohex-3-en-1-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.1 g) as a white solid after trituration with diethyl ether.Mp=117-118° C., LC-MS, MH⁺=276; ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93(d, J=9.0 Hz, 1H); 7.84 (s, 1H); 7.41 (d, J=9.0 Hz, 1H); 5.30-5.00 (m,1H); 4.90-4.70 and 3.80-3.65 (m, 1H); 3.02 and 2.92 (s+s, 3H); 2.60-1.80ppm (s, 6H).

Example 42N-(4-trans-Hydroxycyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

To a mixture of trans 4-aminocyclohexanol hydrochloride (0.46 g, 3.0mmol) and [2,1,3]-benzoxadiazole-5-carboxylic acid (0.33 g, 2.0 mmol) inchloroform (10 ml), were added DMAP (0.24 g, 2.0 mmol), HOBT (0.27 g,2.0 mmol) and triethylamine (1.6 ml). After stirring for 10 minutes,EDCI (1.26 g, 6.6 mmol) in DMF (3 ml) was added and the mixture washeated to 45° C. for 2 h. The solvents were removed under vacuum and thecrude product was purified by silica gel chromatography eluting withethyl acetate/chloroform (3:1) to give a white solid after triturationwith ethyl acetate (0.4 g). Mp=242-243° C., ¹H NMR (300 MHz, DMSO+CDCl₃)δ 8.41-8.39 (m, 1H), 7.95 (dd, J=9.3 and 1.2 Hz, 1H); 7.85 (d, J=9.3 Hz,1H); 7.82 (“s”, NH, 1H), 4.00-3.88 (m, 1H), 3.70-3.50 (m, 2H); 2.15-1.95(m, 4H); 1.55-1.35 ppm (m, 4H).

Example 43N-(trans-4-Hydroxy-4-methylcyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from trans-4-amino-1-methylcyclohexanol using the methoddescribed for Example 42. The product was isolated as a white solid.Mp=208-209° C., ¹H NMR (300 MHz, DMSO+CDCl₃) δ 8.18-8.16 (m, 1H), 7.91(d, J=9.6 Hz, 1H); 7.82 (dd, J=9.6 and 0.9 Hz, 1H); 6.10 (“s”, NH, 1H),4.05-3.90 (m, 1H), 2.00-1.50 (m, 8H); 1.29 ppm (s, 3H).

Example 44 and Example 45N-(cis-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(trans-4-hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a mixture of 1,4-cyclohexanedione mono-ethylene ketal (5.0 g, 32mmol), methylamine hydrochloride (2.16 g, 32 mmol) and triethylamine(6.7 ml), in methanol (100 ml), was added 10% Pd on C (1 g) and themixture was hydrogenated at room temperature (50 PSI) for 2 h. Thesolids were filtered off, washed with methanol (40 ml) and concentratedunder vacuum. The residue was dissolved in methanol (10 ml), THF (50 ml)and 2N HCl (65 ml) and stirred for 18 h. Sodium hydroxide solution(concn) was added to pH 10, the aqueous extracted with dichloromethane(5×100 ml), the combined organics dried (MgSO₄) and concentrated undervacuum to give 4-N-methylaminocyclohexanone (4.97 g). This material wasslowly added to a solution of di-tert-butyl dicarbonate (8.38 g) indichloromethane (80 ml) and the mixture stirred for 2 h. The mixture waswashed with water, dried over MgSO₄, evaporated under vacuum and theresidue chromatographed on silica gel eluting with ethyl acetate/hexane(30:70) to give tert-butyl-(4-cyclohexanone)methylcarbamate as a whitesolid (6.14 g). To a solution of the preceding ketone (0.91 g, 4.0 mmol)in anhydrous THF (100 ml) at −70° C. was added methyl magnesium bromide(6 mmol) and the mixture stirred for 1 h. The mixture was poured into 2NNH₄Cl solution and the pH was adjusted to 7 using citric acid. Theaqueous was extracted with dichloromethane (5×100 ml), the combinedorganics dried (MgSO₄) and evaporated to give an oil (1 g) which waschromatographed on silica gel eluting with ethyl acetate/hexane (1:1) togive tert-butyl(cis-4-hydroxy-4-methylcyclohexyl)methylcarbamate (0.42g) as a colorless oil and as the less polar isomer, andtert-butyl(trans-4-hydroxy-4-methylcyclohexyl)methylcarbamate (0.4 g) asa white solid.tert-Butyl(cis-4-hydroxy-4-methylcyclohexyl)methylcarbamate (0.42 g) wasdissolved in dichloromethane (10 ml) and TFA (2 ml) added, and stirredfor 3 h. The solvent was evaporated under vacuum and the residuedissolved in dichloromethane (10 ml) and conc. HCl (1 ml). The solventwas evaporated and the material was dried over night under high vacuum.The residue was dissolved in DMF (5 ml) and chloroform (3 ml), and[2,1,3]-benzoxadiazole-5-carboxylic acid (0.28 g, 1.7 mmol), DMAP (0.21g 1.7 mmol), HOBT (0.23 g 1.7 mmol) and triethylamine (1.4 ml) wereadded. After 0.1 h, EDCI (1.07 g, 5.6 mmol) was added and after stirringfor 2 h at 45° C., the solvents were evaporated. The residue waschromatographed on silica gel eluting with ethyl acetate/chloroform(3:1) to giveN-(cis-4-hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideas a white solid (0.34 g) after trituration with diethyl ether.Mp=154-155° C., ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, J=9.3 Hz, 1H), 7.82(sb, 1H); 7.46-7.37 (m, 1H); 4.60-4.45 and 3.50-3.30 (m, 1H), 3.05 and2.91 (s+s, 3H); 2.10-1.00 (m, 8H) and 1.29 and 1.16 ppm (s+s, 3H).

N-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas prepared using the procedures above fromtert-butyl(trans-4-hydroxy-4-methylcyclohexyl)methyl carbamate andisolated as a white solid. Mp=175-176° C., ¹H NMR (300 MHz, CDCl₃) δ7.92 (d, J=9.0 Hz, 1H), 7.82 (s, 1H); 7.40 (d, J=9.0 Hz, 1H); 4.60-4.45and 3.60-3.40 (m, 1H), 3.02 and 2.90 (s+s, 3H); 1.90-1.20 (m, 8H) and1.31 ppm (s, 3H).

Example 46 and Example 47N-(cis-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(trans-4-hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

These compounds were prepared using the methods described for Examples44 and 45 using ethyl magnesium bromide.

N-(cis-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas isolated as a white solid. Mp=145-146° C., ¹H NMR (300 MHz, CDCl₃) δ7.91 (d, J=9.0 Hz, 1H), 7.82 (sb, 1H); 7.46-7.37 (m, 1H); 4.60-4.45 and3.50-3.30 (m, 1H), 3.05 and 2.91 (s+s, 3H) and 2.10-0.80 ppm (m, 13H).

N-(trans-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas isolated as a white solid. Mp=110-111° C., ¹H NMR (300 MHz, CDCl₃) δ7.92 (d, J=9.0 Hz, 1H), 7.82 (s, 1H); 7.40 (d, J=9.0 Hz, 1H); 4.60-4.45and 3.60-3.40 (m, 1H), 3.00 and 2.89 (s+s, 3H) and 1.95-0.90 ppm (m,13H).

Example 48N-(cis-4-Ethynyl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared using the methods described for Examples 44 and 45 usingethynyl magnesium bromide and isolated as a white solid. Mp=160-161° C.,¹H NMR (300 MHz, CDCl₃) δ 7.92 (d, J=9.0 Hz, 1H), 7.83 (sb, 1H);7.46-7.36 (m, 1H); 4.65-4.50 and 3.60-3.40 (m, 1H), 3.03 and 2.90 (s+s,3H); 2.60 (s, 1H) and 2.30-1.35 ppm (m, 8H).

Example 49 and Example 50N-(cis-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(trans-4-but-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Title compounds were prepared using the methods described for Examples44 and 45 using but-3-en-1-yl magnesium bromide.

N-(cis-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas isolated as a white solid. Mp=143-144° C., ¹H NMR (300 MHz, CDCl₃) δ7.91 (d, J=9.3 Hz, 1H), 7.82-7.79 (m, 1H); 7.46-7.37 (m, 1H); 5.95-5.70(m, 1H); 5.15-4.90 (m, 2H); 4.60-4.45 and 3.50-3.30 (m, 1H), 3.05 and2.91 (s+s, 3H) and 2.60-1.10 ppm (m, 12H).

N-(trans-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas isolated as a white solid. Mp=145-146° C., ¹H NMR (300 MHz, CDCl₃) δ7.92 (d, J=9.0 Hz, 1H), 7.82 (s, 1H); 7.40 (d, J=9.0 Hz, 1H); 5.95-5.80(m, 1H); 5.12-4.98 (m, 2H); 4.60-4.45 and 3.60-3.40 (m, 1H), 3.01 and2.90 (s+s, 3H) and 2.25-1.20 ppm (m, 12H).

Example 51N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Trans-4-aminocyclohexanol hydrochloride (60.6 g, 0.40 mol) and NaHCO₃(140 g) were dissolved in water (700 ml). Ethyl acetate (500 ml) wasadded and the mixture stirred rapidly using a mechanical stirrer whilsta solution of ethyl chloroformate (48 ml) in ethyl acetate (200 ml) wasadded slowly. The mixture was stirred overnight and then ethyl acetate(1 l) and water (500 ml) were added to dissolve the precipitate. Theaqueous was extracted with ethyl acetate (2×500 ml) and the combinedorganic phases were washed with 2N HCl, dried over Na₂SO₄, and thesolvent evaporated, to give a white solid (73.7 g). This material wasdissolved in dry THF (600 ml) and the solution slowly (˜1 h) added to asuspension of LiAlH₄ (29.6 g) in THF (600 ml). After stirring overnightat 20° C. the mixture was cooled in an ice bath and a solution of sodiumhydroxide (77 g) in water (50 ml) was slowly added. After 1 h, somecelite was added and the mixture was filtered and washed withdichloromethane. The filtrate was dried (MgSO₄) and evaporated undervacuum to give trans-4-methylaminocyclohexanol a white solid (45.9 g).

trans-4-Methylaminocyclohexanol (37.1 g, 0.28 mol),[2,1,3]-benzoxadiazole-5-carboxylic acid (42.7 g, 0.26 mol), DMAP (32 g,0.26 mol), HOBT (11 g, 0.08 mol) and triethylamine (54 ml) weredissolved in dichloromethane (750 ml) and after 15 minutes, EDCI (100 g,0.52 mol) was added and the mixture refluxed for 2 h. The mixture waswashed with 2N HCl (500 ml) and NaHCO₃ solution (500 ml), dried overMgSO₄ and then concentrated under vacuum. The residue waschromatographed on silica gel using ethyl acetate/chloroform (3:1) aseluant to is give the title product as a white solid (37 g) aftertrituration with ethyl acetate. Mp=170-171° C., LC-MS, MH⁺=276; ¹H NMR(300 MHz, CDCl₃, rotamers) δ 7.92 (d, J=9.0 Hz, 1H); 7.82 (s, 1H); 7.40(d, J=9.0 Hz, 1H); 4.60-4.40 and 3.70-3.40 (m, 2H); 2.99 and 2.87 (s+s,3H); 2.20-1.05 ppm (s, 8H).

Example 52N-(4-trans-Hydroxycyclohexyl)-N-D₃-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Title compound was prepared using the procedure described for Example 51replacing LiAlD₄ for LiAlH₄. Mp=170-171° C., ¹H NMR (300 MHz, CDCl₃,rotamers) δ 7.92 (d, J=9.0 Hz, 1H); 7.82 (s, 1H); 7.40 (d, J=9.0 Hz,1H); 4.60-4.40 and 3.70-3.40 (m, 2H) and 2.20-1.05 ppm (s, 8H).

Example 53N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Sodium hydride (0.12 g, 4.8 mmol) followed by methyl iodide (1.1 ml)were added to a solution ofN-(4-trans-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.55 g, 2.0 mmol), in DMF (5 ml), and the mixture stirred at 40° C. for2 h. The DMF was evaporated and the residue was chromatographed onsilica gel eluting with ethyl acetate/chloroform (3:1) to give a whitesolid (0.42 g). Mp=143-144° C., NMR (300 MHz, CDCl₃, rotamers) δ 7.92(d, J=9.0 Hz, 1H); 7.82 (s, 1H); 7.40 (d, J=9.0 Hz, 1H); 4.60-4.40 and3.60-3.00 (m, 2H); 3.37 and 3.29 (s+s, 3H); 2.99 and 2.88 (s+s, 3H);2.30-0.95 ppm (s, 8H).

Example 54N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carbothioamide

N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.91 g, 3.2 is mmol) and phosphorus pentasulfide (1.42 g) were refluxedin toluene (40 ml) for 3 h. The mixture was cooled, filtered through a 2cm layer of silica gel and washed with dichloromethane. Evaporation ofthe solvent and trituration with diethyl ether gave a yellow solid (0.11g). Mp=137-138° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.89-7.83 (m,1H); 7.58-7.55 (m, 1H); 7.36-7.30 (m, 1H); 5.50-5.40 and 3.90-3.75 and3.50-3.00 (m, 2H); 3.44 and 3.38 (s+s, 3H); 3.27 and 3.04 (s+s, 3H);2.30-0.95 ppm (s, 8H).

Example 55N-(4-cis-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(1.26 g, 4.57 mmol), 4-nitrobenzoic acid (1.50 g, 9 mmol) and triphenylphosphine (2.36 g, 9 mmol) were dissolved in THF (60 ml). A solution ofdiethylazodicarboxylate (DIAD, 1.82 g, 9 mmol) in THF (3 ml) was addedslowly and the mixture stirred overnight. The mixture was washed withNaHCO₃ solution (100 ml), the aqueous extracted with ethyl acetate(2×100 ml), dried over Na₂SO₄ and concentrated. The residue was purifiedon a silica gel column using ethyl acetate/hexane (3:1 →1:1) as eluantto give the 4-nitrobenzoate ester as a white solid (1.4 g). Thismaterial was suspended in anhydrous methanol (150 ml) and a solution ofsodium (0.4 g) in anhydrous methanol (50 ml) was added. After stirringat 20° C. for 1 h, the mixture was acidified with conc. HCl andevaporated onto silica gel (10 g). The crude product was chromatographedon silica gel eluting with chloroform/THF/methanol (80:17:3) to give awhite solid after crystallization from dichloromethane/MTBE (0.67 g).Mp=177-179° C., LC-MS, MH⁺=276; ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.91(d, J=9.6 Hz, 1H); 7.82 (s, 1H); 7.40 (d, J=9.6 Hz, 1H); 4.65-4.48 and4.17-3.92 and 3.55-3.37 (m, 2H); 3.05 and 2.91 (s+s, 3H); 2.22-1.25 ppm(s, 8H).

Example 56N-Methyl-N-[trans-4-(2H-tetrazol-2-yl)cyclohexyl]-[2,1,3]-benzoxadiazole-5-carboxamide

N-(4-cis-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.28 g, 1.0 mmol), 1H-tetrazole (0.14 g. 2 mmol) and triphenylphosphine (0.52 g, 2 mmol) were dissolved in THF (25 ml) and a solutionof DIAD (0.40 g, 2 mmol), in THF (5 ml), was added slowly and themixture stirred for 3 h. The mixture was evaporated under vacuum and theresidue was purified on a silica gel column using ethylacetate/hexane/chloroform (35:50:15) as eluant, followed bychromatography eluting with toluene/acetone (80:20), to give a whitecrystalline product after crystallization fromdichloromethane/MTBE/hexane (0.06 g). Mp=172-175° C., ¹H NMR (300 MHz,CDCl₃, rotamers) δ 8.49 (sb, 1H), 7.94 (d, J=9.3 Hz, 1H); 7.86 (s, 1H);7.43 (d, J=9.3 Hz, 1H); 4.85-4.60 and 3.75-3.60 (m, 2H); 3.10-2.90 (m,3H); 2.50-1.80 ppm (s, 8H).

Example 57N-(trans-4-Azidocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a cooled (−25° C.) solution ofN-(4-cis-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.55 g, 2.0 mmol), diphenylphosphorylazide (2.2 m-1.10 mmol) andtriphenyl phosphine (2.62 g, 10 mmol), in THF (50 ml), was slowly addeda solution of DIAD (2.0 ml, 10 mmol), in THF (5 ml), and the mixturestirred for 2 h at −25° C. and for 3 h at 20° C. Water (40 ml) was addedand extracted with ethyl acetate (2×100 ml). The combined organics weredried over MgSO₄, concentrated under vacuum, and the residuechromatographed on silica gel eluting with ethylacetate/hexane/chloroform (2:1:1) to give the product as a white solidafter trituration with diethyl ether (0.29 g). Mp=149-150° C., ¹H NMR(300 MHz, CDCl₃, rotamers) δ 7.92 (d, J=9.3 Hz, 1H); 7.82 (s, 1H); 7.40(d, J=9.3 Hz, 1H); 4.60-4.40 and 3.60-3.10 (m, 2H); 2.99 and 2.88 (s+s,3H); 2.20-1.10 ppm (s, 8H).

Example 58N-(trans-4-Aminocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

N-(trans-4-Azidocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.18 g, 0.6 mmol) was dissolved in pyridine (4 ml), Ph₃P (0.26 g, 1.0mmol) was added, and the mixture stirred for 1 hour at room temperature.Conc. ammonia solution (6 ml) was slowly added and the mixture stirredfor 2 h at 20° C. before evaporating under vacuum and purifying thecrude product on silica gel, eluting withchloroform/methanol/triethylamine (90:10:1), to give a white solid aftertrituration with diethyl ether (0.067 g). Mp=145-146° C., ¹H NMR (300MHz, DMSO+CDCl₃, rotamers) δ 7.93 (d, J=8.7 Hz, 1H); 7.82 (s, 1H); 7.41(d, J=8.7 Hz, 1H); 4.60-4.50 and 3.55-3.35 and 2.80-2.55 (m, 2H); 3.00and 2.88 (s+s, 3H); 2.10-0.90 ppm (s, 8H).

Example 59 and Example 60N-(cis-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(trans-3-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

The title compounds were prepared from benzyl (3-oxocyclohexyl)carbamateusing the procedures described for Example 51. The cis- andtrans-isomers were separated by silica gel chromatography eluting withethyl acetate/chloroform (3:1). Less polar isomer, mp=159-160° C., ¹HNMR (300 MHz, CDCl₃, rotamers) δ 7.90 (d, J=9.3 Hz, 1H); 7.83 (s, 1H);7.41 (d, J=9.3 Hz, 1H); 4.95-4.80 and 4.37-3.95 (m, 2H); 2.99 and 2.87(s+s, 3H); 2.20-1.25 ppm (s, 8H). More polar isomer, mp=131-132° C., ¹HNMR (300 MHz, CDCl₃, rotamers) δ 7.92 (d, J=9.0 Hz, 1H); 7.83 (s, 1H);7.41 (d, J=9.0 Hz, 1H); 4.65-4.50 and 3.90-3.37 (m, 2H); 3.02 and 2.89(s+s, 3H); 2.20-1.00 ppm (s, 8H).

Example 61N-Methyl-N-(3-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

N-(3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.38 g, 1.38 mmol) was dissolved in dichloromethane (10 ml) and PCC (3g) was added and the mixture stirred for 3 h at 20° C. The solvent wasevaporated onto silica gel and the product chromatographed on silica geleluting with ethyl acetate/chloroform (3:1) to give the title product asa white solid after trituration with diethyl ether (0.19 g). Mp=164-165°C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93 (d, J=9.3 Hz, 1H); 7.84 (s,1H); 7.40 (d, J=9.3 Hz, 1H); 4.90-4.67 and 4.00-3.75 (m, 1H); 3.00 (sb,3H); 2.71-1.30 ppm (s, 8H).

Example 62N-Methyl-N-(3,3-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared using the methods described for the preparation of Example 40.Mp=119-120° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93 (d, J=9.0 Hz,1H); 7.84 (s, 1H); 7.41 (d, J=9.0 Hz, 1H); 4.80-4.60 and 3.85-3.70 (m,1H); 2.94 (sb, 3H); 2.40-1.25 ppm (s, 8H).

Example 63N-(2-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from benzyl (2-oxocyclohexyl)carbamate using the proceduresdescribed for Example 51. Only one isomer was observed. Mp=148-149° C.,¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.92-7.86 (m, 2H); 7.51-7.46 (m,1H); 4.50-4.38 and 3.75-3.35 (m, 2H); 3.05 and 2.94 (s+s, 3H); 2.42-1.00ppm (s, 8H).

Example 64N-Methyl-N-(2-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared fromN-(2-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideusing the method described from Example 61. Mp=144-145° C., ¹H NMR (300MHz, CDCl₃, rotamers) δ 7.94-7.74 (m, 2H); 7.53-7.30 (m, 1H); 5.30-5.20and 4.20-4.10 (m, 1H); 3.04 and 2.94 (s+s, 3H); 2.62-1.50 ppm (s, 8H).

Example 65N-Methyl-N-(2,2-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared using the methods described for the preparation of Example 40.Mp=101-102° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.95-7.77 (m, 2H);7.48 (m 1H); 5.10-4.90 and 3.80-3.60 (m, 1H); 3.17 and 3.03 (s+s, 3H);2.30-1.10 ppm (s, 8H).

Example 66 and Example 67N-(2-Hydroxytetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideandN-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

To a solution of 3-aminopentane-1,5-diol (2.38 g, 20 mmol) (Helv. Chim.Acta 1964, 47(8), 2145-2153) and triethylamine (4 ml), indichloromethane (30 ml), was slowly added, at 0° C., a solution of[2,1,3]-benzoxadiazole-5-carboxylic acid chloride (1.82 g, 10 mmol), indichloromethane (20 ml), and the mixture stirred for 1 h. A mixture ofmethanol (30 ml) and 4N potassium carbonate solution (20 ml) was addedand stirred for 3 h. The mixture was evaporated onto silica gel andpurified by silica gel chromatography eluting with ethylacetate/chloroform/methanol (60:30:10) to give, after crystallizationfrom dichloromethane/ethyl acetate/diethyl ether,N-(1,5-dihydroxypentan-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide as awhite solid (Mp: 87-88° C.).N-(1,5-Dihydroxypentan-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide (0.5g, 1.9 mmol), suspended in chloroform (20 ml), was warmed to 45° C. andperiodinane (Dess Martin reagent; 1.6 g) added and stirred for 1 h. Thereaction mixture was evaporated onto silica gel and purified bychromatography, eluting with ethyl acetate/chloroform (60:40) to giveN-(2-hydroxytetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide(0.12 g) as a white solid after trituration with diethyl ether and asthe less polar of two components (Rf: 0.55). Mp=91-92° C., ¹H NMR (300MHz, CDCl₃) δ 8.22 (s, 1H); 7.96-7.81 (m, 2H); 7.10-7.00 and 6.40-6.05(m, 2H); 4.65-4.40 (m, 1H); 4.15-3.70 (m, 2H) and 2.15-0.60 ppm (m, 4H).

The more polar component (Rf: 0.45; 0.035 g) was identified asN-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide.Mp=157-158° C., ¹H NMR (300 MHz, CDCl₃) δ 8.42-8.36 (m, 1H); 7.95-7.86(m, 2H); 7.74-7.66 (m, 1H); 4.77-4.36 (m, 3H); 3.02 (dd, J=7.2 and 17.7Hz, 1H); 2.72 (dd, J=4.5 and 17.7 Hz, 1H) and 2.38-2.07 ppm (m, 2H).

Example 68N-Methyl-N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide

5,6-Dihydro-2H-pyran-2-one (1.0 g, 10.2 mmol) was dissolved in 3 ml of a33% solution of methylamine in ethanol and heated to 55° C. overnight.The solvent was evaporated, the residue dissolved in methanol (20 ml)and conc. HCl (20 ml) and the mixture heated at 95° C. for 2.5 h. Themixture was evaporated to dryness, the residue dissolved in THF (20 ml),dichloromethane (20 ml) and triethylamine (3 ml) and a solution of[2,1,3]-benzoxadiazole-5-carboxylic acid chloride (2.0 g, 11 mmol), indichloromethane (5 ml), added. After stirring is the mixture for 0.75 h,the mixture was washed with 1N HCl and conc. NaHCO₃ solution, dried oversodium sulfate, and concentrated under vacuum. The residue was purifiedon a silica gel column using ethyl acetate/hexane/dichloromethane(70:20:10), to giveN-methyl-N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideas white solid after crystallization from dichloromethane/methanol (0.21g). Mp=169-171° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.97 (d, J=9.0Hz, 1H); 7.90 (s, 1H); 7.40 (d, J=9.0 Hz, 1H); 5.10-4.40 (m, 3H); 3.01(s, 3H); 3.00-2.74 (m, 2H) and 2.60-2.10 ppm (s, 2H).

Example 69N-(2-Hydroxytetrahydro-2H-pyran-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide

To a suspension ofN-(1,5-dihydroxypentan-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide (seeExample 66; 0.9 g, 3.4 mmol), in chloroform (20 ml), was added asolution of acetic anhydride (3 ml) and pyridine (3 ml), drop wise, atroom temperature and the mixture stirred for 2 h. Chloroform (50 ml) wasadded and the mixture washed with 1N HCl and saturated sodiumbicarbonate solution, dried (MgSO₄) and evaporated. The residue waschromatograhed on silica gel, eluting with ethyl acetate/chloroform(3:2), to giveN-(1,5-diacetoxypentan-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide as apale yellow solid.

To a solution of preceding di-acetate (2.4 g, 6.8 mmol), in DMF (40 ml),was added sodium hydride (0.49 g, 20 mmol) and the mixture stirred atroom temperature for 0.25 h. Methyl iodide (1.0 ml) was added, themixture heated at 60° C. for 0.5 h and the solvent evaporated. Theresidue was dissolved in chloroform (100 ml), washed with 1N HCl andsaturated sodium bicarbonate solution, dried (MgSO₄) and evaporated. Theresidue was chromatograhed on silica gel to giveN-(1,5-diacetoxypentan-3-yl)-N-methyl-[2,1,3]-benzoxadiazole-S-carboxamideas a pale brown oil.

To a solution ofN-(1,5-diacetoxypentan-3-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(1.37 g, 3.8 mmol), in methanol (10 ml), was added 10 ml of 3N potassiumcarbonate solution and the mixture stirred at room temperature for 2 h.The methanol was evaporated under vacuum and the residue dissolved inchloroform (100 ml), washed with 1N HCl and saturated sodium bicarbonatesolution, dried (MgSO₄) and evaporated. The crude product waschromatographed on silica gel eluting with ethylacetate/chloroform/methanol (1:1:8%) to give the diol as a pale yellowsolid after trituration with diethyl ether (0.42 g). Mp=90-91° C.

N-(1,5-Dihydroxypentan-3-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamidewas reacted with periodinane as described for Examples 66 and 67 to giveN-(2-hydroxytetrahydro-2H-pyran-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideas a pale yellow solid. Mp=<90° C., ¹H NMR (300 MHz, CDCl₃) δ 7.92 (d,J=9 Hz, 1H); 7.85 (s, 1H), 7.41 (d, J=9 Hz, 1H); 6.40-6.05 (m, 1H);5.20-4.75 (m, 1H); 4.20-3.60 (m, 3H), 3.10-2.80 (m, 3H), and 2.25-1.50ppm (m, 4H).

Example 70trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylN,N-dimethyl glycinate hydrochloride

To a solution ofN-(4-trans-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.55 g, 2.0 mmol) in DMF (10 ml) was added N,N-dimethyl glycine (0.52g, 5.0 mmol), DMAP (0.244 g, 2.0 mmol), HOBT (0.27 g, 2.0 mmol) and EDCI(1.15 g, 6.1 mmol) and the mixture heated at 45° C. overnight. Thesolvent was evaporated under vacuum and the residue dissolved inchloroform (100 ml) washed with water, dried (MgSO₄) and evaporated. Thecrude product was chromatographed on silica gel eluting with ethylacetate/chloroform/methanol (1:1:10%) to give as a white solid,mp=174-175° C. The product was dissolved in 4N HCl in dioxane and thenevaporated to dryness to give the hydrochloride salt. Mp=252-253° C., ¹HNMR (300 MHz, D₂O, 2-rotamers) δ 8.03-7.99 (m, 2H), 7.52-7.49 (m, 1H),4.43-4.34 (m, 0.5H), 4.10 and 4.03 (s, 3H), 3.60-3.40 (m, 0.5H),3.02-2.91 (m, 9H), and 2.22-1.20 ppm (m, 8H).

Example 71trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylL-alaninate hydrochloride

To a solution of N-(tert-butoxycarbonyl)-L-alanine (0.38 g, 2.0 mmol) inchloroform (20 ml) was added CDI (0.32 g, 2 mmol) and the mixturestirred at room temperature for 1.5 h.N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.55 g, 2.0 mmol) was added and the mixture stirred overnight. Water(50 ml) was added and sulfuric-acid (→pH 2) and extracted withdichloromethane (2×70 ml). The combined organics was washed with sodiumbicarbonate solution (50 ml), dried (NaSO₄) and evaporated. The residuewas chromatographed on silica gel eluting with ethyl acetate/hexane(70:30) to give the product as a foam (0.55 g). This material wasdissolved in chloroform (20 ml), TFA (3 ml) added, and the mixturestirred for 1 h. The solvent was evaporated and chloroform (30 ml) and4N HCl in dioxane (3 ml) were added. The solvent was evaporated to givethe title compound as a colorless oil that solidified on standing togive a low melting solid (0.59 g). ¹H NMR (300 MHz, D₂O, 2-rotamers) δ8.03-7.98 (m, 2H), 7.52-7.49 (m, 1H), 4.94-4.64 (m, 1H), 4.43-4.34 (m,0.5H), 4.20-4.10 and 4.10-4.00 (q, J=7.2 Hz, 1H), 3.60-3.44 (m, 0.5H),3.01 and 2.90 (s, 3H), and 2.20-1.20 (m, 8H), 1.55 and 1.45 ppm (d,J=7.2 Hz, 3H).

Example 72N—(R)-Tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from Intermediate 2 and (R)-(+)-tetrahydro-3-furylaminep-toluenesulphonate in a similar manner to that described for thepreparation of Example 1. The title compound was isolated as a whitesolid following re-crystallization from diethyl ether/ethyl acetate.Mp=157-158° C., ¹H NMR (300 MHz, CDCl₃) δ 8.20 (s, 1H), 7.92 (dd, J=1.2and 9.3 Hz, 1H), 7.82 (dd, J=1.2 and 9.3 Hz, 1H), 6.48 (br s, 1H),4.60-4.64 (m, 1H), 4.10-3.80 (m, 4H), 2.50-2.38 (m, 1H), 2.03-1.94 ppm(m, 1H).

Example 73N-Methyl-N—(R)-tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared fromN—(R)-tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide usingthe method described for Example 16. The title compound was isolated asa pale yellow oil. ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.93 (d, J=9.3Hz, 1H), 7.84 (s, 1H), 7.42 (d, J=9.3 Hz, 1H), 5.5-5.25 (m, 0.5H),4.56-4.30 (m, 0.5H), 4.18-3.5 (m, 4H), 3.16-2.90 (br s, 3H), 2.52-1.90ppm (m, 2H).

Example 74trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylglycinate hydrochloride

The title compound was prepared fromN-(4-trans-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideas described for Example 71 and isolated as an off white solid.Mp=245-246° C. (dec), ¹H NMR (300 MHz, D₂O, rotamers) δ 8.05 (d, J=9.3Hz, 1H), 8.00 (s, 1H), 7.51 (dd, J=2.5 and 9.3 Hz, 1H), 4.98-4.64 (m,1H), 4.48-4.37 and 3.60-3.44 (m, total 1H), 3.92 and 3.82 (s, total 2H),3.02 and 2.92 (s, total 3H), 2.03-1.20 ppm (m, 8H).

Example 75 N-2-(4-Morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide

Prepared from Intermediate 1 and 4-(2-aminoethyl)morpholine using themethod described for Example 1 and isolated as a white crystallinesolid. Mp=145-148° C., ¹H NMR (300 MHz, CDCl₃) δ 8.19 (br s, 1H), 7.93(dd, J=1.2 and 9.3 Hz, 1H), 7.85 (dd, J=1.5 and 9.3 Hz, 1H), 6.92 (br s,1H), 3.77-3.73 (m, 4H), 3.62-3.56 (m, 2H), 2.64 (t, J=5.8 Hz, 2H),2.55-2.51 ppm (m, 4H).

Example 76N-Methyl-N-2-(4-Morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochloride

Prepared fromN-2-(4-morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide using themethod described for Example 16. The hydrochloride salt was isolated asan off white solid. Mp=210-212° C., ¹H NMR (300 MHz, D₂O) δ 8.12 (s,1H), 8.05 (d, J=9.4 Hz, 1H), 7.59 (d, J=7.4 Hz, 1H), 4.57-4.18 (m, 2H),4.03 (t, J=6.3 Hz, 2H), 4.00-3.40 (m, 6H), 3.59 (t, J=6.3 Hz, 2H), 3.13ppm (s, 3H).

Example 77N-Methyl-N-tetrahydro-2H-pyran-4-[2,1,3]-benzoxadiazole-5-carbothioamide

The title compound was prepared fromN-methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideusing the procedure described for Example 54 and isolated as a yellowsolid. Mp=174-175° C., ¹H NMR (300 MHz, CDCl₃, rotamers) δ 7.89 and 7.86(dd, J=1.2 and 9.3 Hz, total 1H), 7.58 (d, J=1.2 Hz, 1H), 7.36 and 7.33(dd, J=1.5 and 9.3 Hz, total 1H), 5.78-5.64 (m, 0.5H), 4.20-3.04 (m,2.5H), 3.63-3.55 (m, 1H), 3.48 and 3.08 (s, total 3H), 3.20-3.14 (m,1H), 2.17-1.54 ppm (m, 4H).

Example 78trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylL-valinate hydrochloride

The title compound was prepared fromN-(4-trans-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideas described for Example 71 and isolated as a white solid. Mp=257-258°C. (dec), ¹H NMR (300 MHz, D₂O, rotamers) δ 8.06-7.93 (m, 2H), 7.53-7.47(m, 1H), 4.94-4.70 (m, 1H), 4.43-4.35 and 3.60-3.46 (m, total 1H), 4.00and 3.89 (d, J=3.6 Hz, total 1H), 3.02 and 2.91 (s, total 3H), 2.43-1.62(m, 8H), 1.40-1.20 (m, 1H), 1.10-0.92 ppm (m, 6H).

Example 79trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexylN,N-dimethyl glycinate hydrochloride

To a solution ofN-(trans-4-hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.7 g, 2.4 mmol) in chloroform (10 ml), at 0° C., was addeddimethylaniline (0.44 g, 3.6 mmol) and then chloroacetyl chloride (0.23ml, 2.9 mmol), and the mixture warmed to room temperature and stirredovernight. The reaction mixture was washed with 1N HCl and sodiumbicarbonate solution, dried over MgSO₄ and evaporated. The residue waschromatographed on silica gel eluting with ethyl acetate/chloroform(5:2) to give the chloro acetyl adduct. Dimethylamine (3 ml of a 33%solution in methanol) was added to a solution of the preceding product(0.275 g, 0.75 mmol), in chloroform (15 ml), and the mixture stirred atroom temperature overnight. The mixture was evaporated and the residuewas partitioned between chloroform and water and the organic layerwashed with sodium bicarbonate solution, dried (MgSO₄) and evaporated.The residue was purified by chromatography on silica gel eluting withethyl acetate/chloroform/methanol (1:1.5:7%). The hydrochloride salt wasprepared by adding a mixture of 4N HCl in dioxane to a solution of theproduct in chloroform. The solvents were removed under vacuum and theproduct re-crystallized from methanol/diethyl ether to give the titlecompound (0.13 g) as an off white solid. Mp=201-202° C., ¹H NMR (300MHz, D₂O, 2-rotamers) δ 8.07 (d, J=9.3 Hz, 1H), 8.02 (s, 1H), 7.53 (d,J=9.3 Hz, 1H), 4.45-4.37 and 3.63-3.50 (both m, total 1H), 4.09 and 4.00(both s, total 2H), 3.05, 3.00, 2.95 and 2.91 (all s, total 9H),2.40-1.56 (m, 8H), 1.69 and 1.63 ppm (both s, total 3H).

Example 80N-Methyl-N-tetrahydro-2H-pyran-4-ylmethyl-[2,1,3]-benzoxadiazole-5-carboxamide

Methyl tetrahydro-2H-pyran-4-carboxylate (5 ml, 40.0 mmol) was added toa solution of methylamine (generated by heating a mixture of methylaminehydrochloride and sodium hydroxide pellets) in THF (30 ml) and themixture heated at 110° C. in a bomb reactor overnight. The solvents wereevaporated, the residue dissolved in THF (100 ml), and LiAlH₄ (4.6 g,121 mmol) added, and the mixture heated at 70° C. for 1 h. The mixturewas cooled to 0° C., concentrated NaOH solution added and the THFevaporated. Chloroform (100 ml) was added to the residue and theresulting solid was filtered off and the filtrate concentrated undervacuum to give N-methyl-N-tetrahydro-2H-pyran-4-ylmethylamine as a palebrown oil. The preceding amine (1 g, 7.8 mmol) was dissolved indichloromethane (50 ml), and triethylamine (4 ml) and[2,1,3]-benzoxadiazole-5-carbonylchloride (1.7 g, 9.3 mmol), as asolution in dichloromethane (20 ml), were added, slowly. The mixture wasstirred at room temperature for 1 h, the mixture washed with 1N HCl (20ml), and saturated sodium bicarbonate solution (20 ml), dried (MgSO₄)and evaporated. The residue was purified by silica gel chromatographyeluting with ethyl acetate/chloroform (3:1) to give the title compoundas a pale brown oil. ¹H NMR (300 MHz, CDCl₃, 2-rotamers) δ 7.93 (d,J=9.3 Hz, 1H), 7.83 (br s, 1H), 7.38-7.45 (m, 1H), 4.10-3.90 (m, 2H),3.52-3.20 (m, 4H), 3.13 and 3.05 (both s, total 3H), 2.18-1.80 (m, 1H),1.73-1.40 ppm (m, 4H).

Example 81trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexylglycinate hydrochloride

N-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide(0.49 g, 2.0 mmol) was suspended in THF (40 ml) and dimethylaniline (0.3ml, 2.2 mmol)) was added. The mixture was heated at 70° C. for 0.1 hbefore adding bromoacetyl bromide (0.2 ml, 2.4 mmol) and stirring at 70°C. for 3 h. The mixture was cooled to room temperature before addingchloroform (50 ml) and washing with water (50 ml), 1 N HCl (25 ml) andsaturated sodium bicarbonate solution (25 ml). The organic was driedover MgSO₄, evaporated and the residue purified by chromatography onsilica gel eluting with ethyl acetate/chloroform (1:1) to give the bromoacetyl derivative as a white solid (0.63 g, 76%; Mp=133-134° C.).

To a solution of the preceding acetyl bromide (0.61 g, 1.5 mmol) in DMF(8 ml) was added sodium azide (0.59 g, 9 mmol) and the mixture heated at50° C. for 3 h. The DMF was removed under vacuum and the residuepartitioned between chloroform and water. The chloroform extract waswashed with 1N HCl and saturated sodium bicarbonate solution, dried(MgSO₄) and evaporated to give the desired azide. To this material (0.56g, 1.5 mmol) was added pyridine (5 ml) and triphenyl phosphine (0.63 g,2.4 mmol) and the mixture stirred at room temperature for 0.5 h) beforeadding conc^(n) ammonium hydroxide solution (10 ml) and stirring for afurther 2 h at room temperature. The pyridine was removed under vacuumand the residue was purified by chromatography on silica gel elutingwith ethyl acetate/hexane (1:1) followed bychloroform/methanol/triethylamine (90:10:3) to givetrans-4-[(2,1,3-benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexylglycinate as a yellow solid (0.42 g). The hydrochloride salt wasprepared as described previously and was isolated as a white solid.Mp=188-189° C. ¹H NMR (300 MHz, D₂O, 2-rotamers) δ 8.05 (d, J=9.3 Hz,1H), 7.99 (s, 1H), 7.50 (d, J=9.3 Hz, 1H), 4.45-4.37 and 3.63-3.50 (bothm, total 1H), 3.84 and 3.71 (both s, total 2H), 3.03 and 2.93 (both s,total 3H), 2.40-1.56 (m, 8H), 1.66 and 1.59 ppm (both s, total 3H).

II. Biological Methods Example 82 In Vivo Electrophysiology

The electrophysiological effects of invention compounds were tested invivo in anesthetized animals according to the following procedures.

Animals are maintained under anesthesia by phenobarbital administeredusing a Hamilton syringe pump. Stimulating and recording electrodes areinserted into the perforant path and dentate gyrus of the hippocampus,respectively. Once electrodes are implanted, a stable baseline of evokedresponses are elicited using single monophasic pulses (100 μs pulseduration) delivered at 3/min to the stimulating electrode. Field EPSPsare monitored until a stable baseline is achieved (about 20-30 min),after which a solution of test compound is injected intraperitoneallyand evoked field potentials are recorded. Evoked potentials are recordedfor approximately 2 h following drug administration or until theamplitude of the field EPSP returns to baseline. In the latter instance,it is common that an iv administration is also carried out with anappropriate dose of the same test compound.

Example 83 Inhibition of d-Amphetamine Stimulated Locomotion

Male CD1 mice, 25-30 gm body weight, were brought into the experimentalroom and allowed at least 30 min of acclimation. Each mouse was placedinto the testing enclosure with an infrared beam array thatautomatically monitors the animal's activity. Mice were habituated inthe testing enclosure for 20 min, and then returned to their home cage.Mice were dosed intraperitoneally with test compound in appropriatevehicle 5 minutes before d-Amphetamine injection. Ten minutes afterd-Amphetamine injection, mice were tested for locomotor activity for atotal of 15 minutes. The data was computer collected and expressed as“arbitrary movement units.” All data were analyzed by comparing thegroups treated with the test compound to the vehicle control group.Statistical analysis was performed by ANOVA followed by Dunnet's t-testwhere P less than 0.05 were considered to be significantly different.

While the invention has been described with reference to specificmethods and embodiments, it will be appreciated that variousmodifications may be made without departing from the invention.

1. A compound according to the formula:

wherein: W is oxygen, sulfur or CH═CH; X, Y and Z are independentlyselected from the group consisting of —N, or —CR, wherein: R is H, —Br,—Cl, —F, —CN, —NO₂, —OR¹, —SR¹, —NR¹ ₂, —C₁-C₆ branched or un-branchedalkyl, which may be un-substituted or substituted, wherein: R¹ is H,—C₁-C₆ branched or un-branched alkyl which, may be un-substituted orsubstituted, F═O or S, A is H, or —C₁-C₆ branched or un-branched alkyl,which may be un-substituted or substituted, —C₂-C₆ branched orun-branched alkenyl, which may be un-substituted or substituted, —C₂-C₆branched or un-branched alkynyl, which may be un-substituted orsubstituted, —C₃-C₇ cycloalkyl which may be un-substituted orsubstituted, —C₃-C₇ alkylcycloalkyl which may be un-substituted orsubstituted, aryl or heterocycle which may be un-substituted orsubstituted, alkylaryl which may be un-substituted or substituted,alkylheterocycle which may be un-substituted or substituted n=0, 1, 2,3, 4, 5, or 6;

is a —C₃-C₇ cycloalkyl which may be un-substituted or substituted, a—C₄-C₇ azacycloalkyl, which may be un-substituted or substituted, a—C₇-C₁₀ bicycloalkyl which may be un-substituted or substituted, a—C₇-C₁₀ azabicycloalkyl which may be un-substituted or substituted, arylwhich may be un-substituted or substituted or a heterocycle which may beun-substituted or substituted; B is —C═, C—R^(a), O, N, S, C═O, S═O orSO₂; R^(a) is H, a halogen (preferably F), OH, Oalkyl, cyano, or a—C₁-C₆ alkyl group which is un-substituted or substituted and whichoptionally, forms a C₃-C₇ cycloalkyl group with D; and D is absent whenB is O, S, C═O, S═O or SO₂, or if present, is bonded to B when B is —C═,—C—R^(a) or N, and is H, a halogen (preferably F), OR^(b), a —C₁-C₆branched or un-branched alkyl, which may be un-substituted orsubstituted and which optionally, forms a C₃-C₇ cycloalkyl group withR^(a), a —C₂-C₆ branched or un-branched alkenyl, which may beun-substituted or substituted, a —C₂-C₆ branched or un-branched alkynyl,which may be un-substituted or substituted, a —C₃-C₇ cycloalkyl whichmay be un-substituted or substituted, an aryl which may beun-substituted or substituted, a heterocycle which may be un-substitutedor substituted, a —C₂-C₇ carboxyalkyl which may be un-substituted orsubstituted, a carboxyaryl which may be un-substituted or substituted, acarboxyheteroaryl which may be un-substituted or substituted, a C₁-C₇sulfonylalkyl which may be un-substituted or substituted, a sulfonylarylwhich may be un-substituted or substituted or a sulfonylheteroaryl whichmay be un-substituted or substituted, or when B is —C—R^(a), R^(a) and Doptionally form a ═N—R^(c) or a ═N—OR^(c) group with B, wherein R^(c) isH or an unsubstituted or substituted C₁-C₇ alkyl group; and R^(b) is H,a —C₁-C₇ alkyl group which may be branched or un-branched,un-substituted or substituted or a —C₂-C₇ acyl group which may beun-substituted or substituted; or a pharmaceutically acceptable salt,solvate, pro-drug or polymorph thereof.
 2. Compounds of claim 1according to formula II:

wherein: A is —C₁-C₆ branched or un-branched alkyl, which may beun-substituted or substituted, a —C₃-C₇ cycloalkyl which may beun-substituted or substituted; n is 0, 1, 2, or 3; and B is C—R^(a), C═Oor O; R^(a) is H, OH, alkyl or F; and D is absent, is H or OH when R^(a)is H or alkyl, or is F when R^(a) is F, or a pharmaceutically acceptablesalt, solvate, or polymorph thereof.
 3. Compounds of claim 1 accordingto formula III:

wherein: A is a C₁-C₆ alkyl which may be substituted or un-substituted Bis C—R^(a), O or C═O; R^(a) is H, F, —OH or alkyl and D is absent (whenB is O), is H or OH when R^(a) is H or alkyl, or is F when R^(a) is F,or a pharmaceutically acceptable salt, solvate, or polymorph thereof. 4.Compounds of claim 1 according to formula IV:

wherein: A is a C₁-C₆ alkyl which may be substituted or un-substituted,n is 0, 1 or 2, or a pharmaceutically acceptable salt, solvate, orpolymorph thereof.
 5. Compounds of claim 1 according to formula V:

wherein: A is a C₁-C₆ alkyl which may be substituted or un-substituted,R¹ is H, F, or C₁-C₄ alkyl, R² is H, F, CN, a heterocycle which may besubstituted or un-substituted or OR³, R³ is H, C₁-C₆ alkyl which may besubstituted or un-substituted, or a pharmaceutically acceptable salt,solvate, or polymorph thereof.
 6. Compounds of claim 1 according toformula VI:

wherein: A is a C₁-C₆ alkyl which may be substituted or un-substituted,R is H, or C₁-C₄ alkyl, or a pharmaceutically acceptable salt, solvate,or polymorph thereof.
 7. Compounds of claim 1 according to formula VII:

wherein: B is C—R^(a), O or C═O; R^(a) is H, F, —OH or alkyl and D isabsent (when B is O), is H or OH when R^(a) is H or alkyl, or is F whenR^(a) is F, or a pharmaceutically acceptable salt, solvate, or polymorphthereof.
 8. Compounds of claim 1 according to formula VIII:

wherein: B is C—R^(a), O or C═O; R^(a) is H, F, —OH or alkyl and D isabsent (when B is O), is H or OH when R^(a) is H or alkyl, or is F whenR^(a) is F, or a pharmaceutically acceptable salt, solvate, or polymorphthereof.
 9. Compounds of claim 1 according to formula IX:

wherein: A is a C₁-C₆ alkyl which may be substituted or un-substituted,R¹ is H, or C₁-C₄ alkyl, R² is H, or a C₁-C₆ alkyl which may besubstituted or un-substituted, R³ is H, or a C₁-C₆ alkyl which may besubstituted or un-substituted, R⁴ is H, or a C₁-C₆ alkyl which may besubstituted or un-substituted, or a pharmaceutically acceptable salt,solvate, or polymorph thereof.
 10. A compound according to Formulaswhich is: N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclopentyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide11. A compound according to Formula IX which is:trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylN,N-dimethyl glycinate hydrochloridetrans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylL-alaninate hydrochloridetrans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylL-valinate hydrochloridetrans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexylN,N-dimethyl glycinate hydrochloridetrans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexylglycinate hydrochloridetrans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexylglycinate hydrochloride
 12. A compound according to Formulas I-VIIIwhich is: N-Cycloheptyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4,4-Dimethylcyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-spiro[2.5]oct-6-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclobutyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclohexyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclopentyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclobutyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-D₃-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-(Tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Ethyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclohexyl-N-ethyl-[2,1,3]-benzoxadiazole-5-carboxamideN—(Cyclohexylmethyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Benzyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(tetrahydrofuran-2-ylmethyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-pyridin-3-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-phenyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Cyclopropyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Tetrahydro-2H-pyran-4-yl-N-(2,2,2-trifluoroethyl)-[2,1,3]-benzoxadiazole-5-carboxamidetert-Butyl-4-[([2,1,3]-benzoxadiazol-5-ylcarbonyl)(methyl)amino]piperidine-1-carboxylateN-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochlorideN-Methyl-N-(1-methylpiperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(1-Acetylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(1-Formylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-[1-(methylsulfonyl]piperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzothiadiazole-5-carboxamideN-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(1-oxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-tetrahydro-2H-pyran-4-ylquinoxaline-6-carboxamideN-[4-(Hydroxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-[4-(Methoxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4,4-Difluorocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4-fluorocyclohex-3-en-1-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4-trans-Hydroxycyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Hydroxy-4-methylcyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-4-Ethynyl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(4-trans-Hydroxycyclohexyl)-N-D₃-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carbothioamideN-(4-cis-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-[trans-4-(2H-tetrazol-2-yl)cyclohexyl]-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Azidocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-4-Aminocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(cis-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-(trans-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(3-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(3,3-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(2-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(2-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(2,2-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(2-Hydroxytetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamideN-(2-Hydroxytetrahydro-2H-pyran-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamideN—(R)-Tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N—(R)-tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamideN-2-(4-Morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamideN-Methyl-N-2-(4-morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamidehydrochlorideN-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carbothioamideN-Methyl-N-tetrahydro-2H-pyran-4-ylmethyl-[2,1,3]-benzoxadiazole-5-carboxamide13. A pharmaceutical composition comprising an effective amount of acompound according to claim 1 in combination with a pharmaceuticallyacceptable carrier, additive or excipient.
 14. The composition accordingto claim 13 wherein said compound comprises about 0.5% to about 75% byweight of said composition and said carrier, additive or excipientcomprises about 25% to about 95.5% of said composition.
 15. A method forthe treatment of a mammalian subject, wherein the subject suffers from ahypoglutamatergic condition or a deficiency in the number or strength ofexcitatory synapses or in the number of AMPA receptors, such that memoryor other cognitive functions are impaired, said method comprisingadministering to said subject, in a pharmaceutically acceptable carrier,an effective amount of a compound according to claim
 1. 16. A method forthe treatment of a mammal wherein the subject suffers from ahypoglutamatergic condition or deficiencies in the number or strength ofexcitatory synapses or in the number of AMPA receptors such that acortical/striatal imbalance occurs leading to schizophrenia orschizophreniform behavior, said method comprising administering to saidsubject, in a pharmaceutically acceptable carrier, an effective amountof a compound according to claim
 1. 17. The method according to claim 15wherein said condition is schizophrenia
 18. The method according toclaim 15 wherein said condition is Parkinson's disease.
 19. A method oftreating ADHD in a patient in need thereof, said method comprisingadministering to said patient an effective amount of a compoundaccording to claim
 1. 20. A method of treating Rett Syndrome in apatient in need thereof, said method comprising administering to saidpatient an effective amount of a compound according to claim
 1. 21. Amethod of treating Fragile-X Syndrome in a patient in need thereof, saidmethod comprising administering to said patient an effective amount of acompound according to claim
 1. 22. A method of treating respiratorydepression in a patient in need thereof, said method comprisingadministering to said patient an effective amount of a compoundaccording to claim
 1. 23. A method of treating respiratory depression ina patient in need thereof, said method comprising administering to saidpatient an effective amount of a compound according to claim 1 incombination with an opiate or opioid analgesic.
 24. A method of treatingrespiratory depression in a patient in need thereof, said methodcomprising administering to said patient an effective amount of acompound according to claim 1 in combination with an anesthetic agentsuch as propofol or barbiturates.
 25. A method of treating breathingrelated sleep disorders or sleep apnea in a patient in need thereof,said method comprising administering to said patient an effective amountof a compound according to claim
 1. 26. A method of treating Alzheimer'sdisease in a patient in need thereof, said method comprisingadministering to said patient an effective amount of a compoundaccording to claim
 1. 27. A method of treating Alzheimer's disease in apatient in need thereof, said method comprising administering to saidpatient an effective amount of a compound according to claim 1 incombination with acetylcholinesterase inhibitors. 28-38. (canceled)